Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
- Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
- 04/15/2024
|
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
- Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
- 04/03/2024
|
8 Upcoming Dividend Increases
- A list of top stocks expected to raise dividends in the upcoming week, with increases averaging 8.4% and median 6.8%. Companies included in the list have consistently grown their dividends for at least five years. Comparison of historical returns of stocks to benchmark SCHD, with JPM being the top performer.
- 03/28/2024
|
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
- SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens.
- 03/19/2024
|
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
- Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
- 02/27/2024
|
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
- SECAUCUS, N.J. , Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m.
- 02/23/2024
|
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
- Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
- 02/15/2024
|
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
- Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
- 02/13/2024
|
3 Medtech Stocks Likely to Top Estimates This Earnings Season
- Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
- 02/13/2024
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Strength of the base business bodes well for Quest Diagnostics (DGX).
- 02/06/2024
|
Quest Diagnostics: Post-COVID Normalization Pretty Much Done
- Quest Diagnostics is a leading provider of diagnostic information services, offering laboratory testing, genomics, and other diagnostic solutions. During 2020, COVID-19 detection tests played an important role in the atypical growth of the top line and the substantial increase in margins. This factor has already been completely normalized. From this base point, I expect low-single-digit organic growth and improved margins, which, together with a dividend yield of 2.4%, should be enough to obtain an attractive return.
- 02/05/2024
|
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
- Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
- 02/01/2024
|
Quest Diagnostics (DGX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
- Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/01/2024
|
Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down
- Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.
- 02/01/2024
|
Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates
- Quest Diagnostics (DGX) came out with quarterly earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.98 per share a year ago.
- 02/01/2024
|
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
- Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.
- 01/26/2024
|
Oncology Space Gains Momentum: 3 Stocks in Focus
- Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.
- 01/23/2024
|
3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024
- Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.
- 01/19/2024
|
Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study
- Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.
- 01/19/2024
|
The Top 3 Stocks in the High-Potential ‘Cancer Testing' Market
- Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.
- 01/18/2024
|
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
- SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 1, 2024, before the market opens.
- 01/17/2024
|
Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics
- Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.
- 01/15/2024
|
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 01/10/2024
|
Quest Diagnostics (DGX) to Boost Lab Services With New Buyout
- Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.
- 01/09/2024
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
- 01/03/2024
|
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel
- Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.
- 12/20/2023
|
Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal
- Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.
- 12/18/2023
|
Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden
- Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
- 12/08/2023
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.
- 11/30/2023
|
Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening
- Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.
- 11/22/2023
|
Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service
- Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.
- 11/13/2023
|
Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips
- Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.
- 10/24/2023
|
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates
- Quest Diagnostics (DGX) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.36 per share a year ago.
- 10/24/2023
|
Quest Diagnostics profit falls 12%, but beats estimate
- Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.17 a share, in the year-ago quarter. Adjusted third-quarter profit fell to $2.22 a share from $2.36 a share, and beat the FactSet consensus estimate of $2.19 a share.
- 10/24/2023
|
Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?
- Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.
- 10/19/2023
|
Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes
- Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.
- 10/18/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of October 15
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 10/14/2023
|
Quest Diagnostics (DGX) to Boost Lab Services With New Pact
- Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.
- 10/06/2023
|
Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023
- SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023, before the market opens.
- 10/04/2023
|
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/02/2023
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.
- 09/20/2023
|
Quest Diagnostics (DGX) to Aid Health Equity With New Pact
- Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.
- 09/14/2023
|
Quest Diagnostics to Speak at the Baird 2023 Global Healthcare Conference
- SECAUCUS, N.J. , Sept. 8, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023, at 2:00 p.m.
- 09/08/2023
|
Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod
- Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.
- 09/01/2023
|
Why Is Quest Diagnostics (DGX) Down 0.9% Since Last Earnings Report?
- Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
- 08/25/2023
|
3 Pharma Stocks to Buy as Summer COVID Cases Spike
- Covid-19 related stocks started spiking again this week. Driven primarily by reports about new variants and increasing spread.
- 08/23/2023
|
Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
- Quest Diagnostics has a strong Q2 with a slight beat on EPS and revenue. Quest's base business appears to be recovering from the pandemic and pulled in $2.30B in revenue. Despite fading COVID-related revenue, Quest updated their full-year 2023 revenues to $9.12B -$9.22B. The post-COVID labor market is posing challenges, including high turnover and elevated labor costs. As a result, I have downgraded my conviction level from 5/5 to 4/5.
- 08/15/2023
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.
- 08/14/2023
|
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
- Biogen and Eli Lilly both have treatments to help reduce cognitive decline in Alzheimer's patients. But the key to their effectiveness is in treating people who have the disease in its early stages.
- 08/09/2023
|
Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023
- Walking into the latter half of 2023, we're looking at a very different stock market than a year ago. Despite elevated interest rates and ongoing inflation, the S&P 500 is up for the fifth consecutive month.
- 08/02/2023
|
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer's disease
- Quest Diagnostics Inc. DGX, +0.10% said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer's disease to market and it's now available for consumer purchase. The test helps assess the risk of getting the disease based on the brain protein beta amyloid which contributes to it.
- 07/31/2023
|
Quest Diagnostics launches Alzheimer's blood test for consumers
- Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.
- 07/31/2023
|
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates
- Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.23 per share. This compares to earnings of $2.36 per share a year ago.
- 07/26/2023
|
Quest Diagnostics beats profit estimates as routine testing picks up
- Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pandemic.
- 07/26/2023
|
Final Trades: Quest Diagnostics, Keysight & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 07/18/2023
|
Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?
- Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.
- 07/18/2023
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.
- 07/18/2023
|
Quest Diagnostics (DGX) Brings New Test for Prostate Cancer
- Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.
- 07/14/2023
|
Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test
- The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.
- 07/10/2023
|
Quest Diagnostics (DGX) Presents New Data on Disease Testing
- Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.
- 07/03/2023
|
Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio
- Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.
- 06/22/2023
|
Quest Diagnostics to Release Second Quarter 2023 Financial Results on July 26, 2023
- SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023, before the market opens.
- 06/21/2023
|
Quest Diagnostics (DGX) Partners to Offer New Testing Service
- Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.
- 06/20/2023
|
Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes
- Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.
- 06/06/2023
|
Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference
- SECAUCUS, N.J. , June 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Global Healthcare Conference.
- 06/02/2023
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.
- 06/02/2023
|
Zuckerberg unveils Meta's newest VR headset days before Apple reveals its own
- The Meta Quest 3 is the successor to the Quest 2 headset that was released in the fall of 2020 at a starting price of $299.
- 06/01/2023
|
Quest Diagnostics: Healthier Diagnosis
- Quest Diagnostics Incorporated has seen modest growth in recent years, although serial buybacks have increased growth on a per-share basis to attractive percentages. The company has been resilient and diversified and has seen a boom and consequential bust cycle in Covid-19-related testing revenues. With the pandemic fading, the headwind to reported growth should subside, potentially being the trigger for a Quest Diagnostics Incorporated re-rating here.
- 05/30/2023
|
Want Growing Passive Income? Consider Buying This Stock
- Quest Diagnostics' revenue and earnings fell in Q1. The company's low payout ratio should support future dividend growth.
- 05/24/2023
|
Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease
- Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
- 04/30/2023
|
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
- Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
- 04/27/2023
|
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
- Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.
- 04/20/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of April 16
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 04/16/2023
|
Quest Diagnostics (DGX) Advances Access to Transplant Services
- Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
- 04/10/2023
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- 04/06/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of April 2
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 04/02/2023
|
5 Upcoming Dividend Increases To Start Q2
- All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.1% and a median increase of 7.6%.
- 03/30/2023
|
Quest Diagnostics (DGX) Upgraded to Buy: What Does It Mean for the Stock?
- Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/29/2023
|
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
- Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.
- 03/28/2023
|
Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels
- Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers
- 03/27/2023
|
Quest Diagnostics (DGX) Advances Transplant Testing Service
- These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.
- 03/23/2023
|
Quest Diagnostics (DGX) Acquires Northern Light Laboratory
- Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.
- 03/21/2023
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- 03/21/2023
|
Quest Diagnostics (DGX) Updates Its Strategic Focus, LT Growth
- Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
- 03/20/2023
|
Quest Diagnostics Remains A Solid Long-Term Company
- Quest Diagnostics core business is experiencing strong growth and has a structure that could potentially exceed market expectations. The current valuation seems very promising and making an entry at these prices I think would offer good returns.
- 03/20/2023
|
Is This Healthcare Stock a Buy for Dividend Growth Investors?
- Quest Diagnostics' revenue and earnings dropped in 2022. Decent dividend growth should be in the company's future.
- 03/07/2023
|
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 03/03/2023
|
Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio
- Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.
- 02/28/2023
|
Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up
- Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.
- 02/21/2023
|
Walmart, Home Depot Among 15 Companies To Announce Dividend Increases In Second Half Of February
- When it comes to annual dividend increases, February is the highlight of the year. There were at least 27 dividend boosts that were announced from a wide variety of companies. Widely held companies 3M, PepsiCo, and Coca-Cola all boosted their dividends in the first half of the month, with Pepsi announcing a 10% increase.
- 02/19/2023
|
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
- Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.
- 02/15/2023
|
Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down
- Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.
- 02/02/2023
|
Quest Diagnostics (DGX) Q4 2022 Earnings Call Transcript
- Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2022 Earnings Conference Call February 2, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Patrick Donnelly - Citi Jack Meehan - Nephron Research AJ Rice - Credit Suisse Pito Chickering - Deutsche Bank Brian Tanquilut - Jefferies Kevin Caliendo - UBS Andrew Brackmann - William Blair Derik de Bruin - Bank of America Elizabeth Anderson - Evercore ISI Rachel Vatsndal - JP Morgan Operator Welcome to the Quest Diagnostics Fourth Quarter and Full Year 2002 conference call. At the request of the company, this call is being recorded.
- 02/02/2023
|
Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.21% and 3.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/02/2023
|
Quest Diagnostics revenue declines amid steep fall in COVID tests
- Quest Diagnostics Inc. DGX, +0.11% posted net income of $101 million, or 87 cents a share, for the fourth quarter, down from $390 million, or $3.12 a share, in the year-earlier period. Adjusted per-share earnings came to $1.98, ahead of the $1.91 FactSet consensus.
- 02/02/2023
|
Quest Diagnostics raises quarterly dividend by 7.6% to 71 cents a share, boosts share buyback by $1 billion
- Quest Diagnostics Inc. DGX, +0.11% said Thursday its board has agreed to raise its quarterly dividend by 7.6% to 71 cents a share. The new dividend will be payable April 24 to shareholders of record as of April 10.
- 02/02/2023
|
3 Dividend Kings Among 22 Companies To Announce Annual Dividend Increases In First Half Of February
- There is a slew of dividend increases coming in February, including from dividend kings Genuine Parts, 3M, and PepsiCo in the first half of the month. Other popular stocks that traditionally announce annual increases in early February are Sherwin-Williams and Cisco.
- 01/29/2023
|
Quest Diagnostics (DGX) to Report Q4 Earnings: What's in Store?
- Quest Diagnostics (DGX) ramps up investments to accelerate growth in the base business, particularly in advanced diagnostics and direct-to-consumer testing.
- 01/24/2023
|
Quest Diagnostics to Release Fourth Quarter and Full Year 2022 Financial Results on February 2, 2023
- SECAUCUS, N.J. , Jan. 20, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023, before the market opens.
- 01/20/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of January 8
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 01/08/2023
|
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/29/2022
|
Final Trades: Quest Diagnostics, Treasurys & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 12/22/2022
|
Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access
- Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.
- 12/09/2022
|
Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay
- Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.
- 12/06/2022
|
Quest Diagnostics Is a Wreck Amidst Covid-19 Testing Declines
- One of the companies that benefitted hugely from the Covid-19 pandemic was diagnostic testing company Quest Diagnostics Inc ( DGX , Financial), which operates a national network of full-service clinical labs and over 2,200 patient service centers. That major tailwind has since subsided, and while there are still growth opportunities for clinical testing companies, the reduction in Covid-related income has made a wreck of the stock.
- 10/31/2022
|
Here's Why Quest Diagnostics Stock Should Be in Your Portfolio
- Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been trading within a boxed range from $126 to $146 for the majority of 2022.
- 10/31/2022
|
COVID-19 testing volume has 'come down,' Quest Diagnostics CEO says
- Quest Diagnostics CEO Steve Rusckowski joins Yahoo Finance Live to discuss the state of the coronavirus pandemic, testing demand, manufacturing capacity, and the outlook for the industry.
- 10/24/2022
|
Quest Diagnostics (DGX) Just Overtook the 200-Day Moving Average
- Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
- 10/21/2022
|
Why Quest Diagnostics Stock Jumped Today
- Growth in the lab testing titan's core business is accelerating.
- 10/20/2022
|
Quest Diagnostics stock pops as it raises full-year guidance
- Yahoo Finance Live anchors Seana Smith, Josh Schafer and Dave Briggs looks at Quest Diagnostics shares following its boosted guidance.
- 10/20/2022
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q3 2022 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2022 Earnings Conference Call October 20, 2022 8:30 AM ET Company Participants Shawn Bevec - VP of IR Steve Rusckowski - Chairman, President & Chief Executive Officer Jim Davis - CEO Sam Samad - CFO Conference Call Participants Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Brian Tanquilut - Jefferies A.J. Rice - Credit Suisse Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Operator Welcome to the Quest Diagnostics Third Quarter 2022 Conference Call.
- 10/20/2022
|
Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View
- Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.
- 10/20/2022
|
Quest Diagnostics (DGX) Tops Q3 Earnings and Revenue Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 8.76% and 5.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/20/2022
|
Quest Diagnostics earnings fall but beat expectations, even as COVID-19 testing revenue drops 55%
- Quest Diagnostics Inc. DGX, -2.25% reported Thursday third-quarter profit and revenue that fell from a year ago but beat expectations, as base business performance rebounding in the latter part of the quarter to help offset inflationary pressure and declining COVID-19 volumes. The health diagnostics information services company's stock was still inactive in the premarket.
- 10/20/2022
|
Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?
- The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.
- 10/14/2022
|
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/11/2022
|
Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing
- Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.
- 10/03/2022
|
Eli Lilly, EQT, Cash Cows ETF, Northrop Grumman And This Diagnostics Company Feature On CNBC's Final Trade - Pacer US Cash Cows 100 ETF (BATS:COWZ), Quest Diagnostics (NYSE:DGX)
- On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said Pacer US Cash Cows 100 ETF (BATS: COWZ) is “a factor-b
- 10/03/2022
|
Final Trades: Eli Lilly, Quest Diagnostics, Northrop Grumman & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 09/30/2022
|
Quest Diagnostics to Release Third Quarter 2022 Financial Results on October 20, 2022
- SECAUCUS, N.J. , Sept. 27, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2022 financial results on Thursday, October 20, 2022, before the market opens.
- 09/27/2022
|
Must Read: Quant Ratings Updated on 68 Stocks
- U.S. stocks have continued to slip as Wall Street prepares for another rate hike from the Federal Reserve. After wobbling between small gains and losses throughout the trading session, the S&P 500 closed higher 0.7% on Monday.
- 09/20/2022
|
Quest Diagnostics (DGX) to Offer Lab Services for Lee Health
- Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.
- 09/20/2022
|
Quest Diagnostics: The Market Is Overlooking Long-Term Prospects
- Quest Diagnostics has been a pillar in my “Healthy Dividends” portfolio thanks to a safe dividend and long-term growth prospects. Quest has been a key player in the battle against COVID-19 thanks to their ability to handle high testing demand.
- 09/15/2022
|
Better Monkeypox Stock: SIGA Technologies vs. Quest Diagnostics
- One sells a treatment. The other sells a diagnostic test.
- 09/15/2022
|
Quest Diagnostics: Valuation Looks Good As Covid Testing Demand Tapers
- The Health Care sector sports relative strength during the latest market drop. Quest Diagnostics should see profits fall somewhat as Covid wanes, but there are other upside risks in this low P/E stock.
- 09/09/2022
|
Quest Diagnostics to Speak at the Morgan Stanley 20th Annual Global Healthcare Conference
- SECAUCUS, N.J. , Sept. 8, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference.
- 09/08/2022
|
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 09/01/2022
|
3 Top Monkeypox Stocks to Buy Right Now
- With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts.
- 08/24/2022
|
Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids
- With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
- 08/17/2022
|
10 defensive stocks that can also provide you with growth and dividends over the long term
- The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.
- 08/10/2022
|
These 3 Companies Are Taking on Monkeypox
- A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
- 08/04/2022
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2022 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2022 Earnings Conference Call July 21, 2022 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Steve Rusckowski - Chairman, President & Chief Executive Officer Jim Davis - Chief Executive Officer-Elect Mark Guinan - Chief Financial Officer Sam Samad - Executive Vice President & Incoming-Chief Financial Officer Conference Call Participants Brian Tanquilut - Jefferies A.J. Rice - Credit Suisse Jack Meehan - Nephron Research Patrick Donnelly - Citi Pito Chickering - Deutsche Bank Ricky Goldwasser - Morgan Stanley Rachel Vatnsdal - JPMorgan Operator Good morning.
- 07/21/2022
|
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
- Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.
- 07/21/2022
|
Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/21/2022
|
Quest Diagnostics profit drops but testing firm raises 2022 view
- Quest Diagnostics Inc. DGX, -1.33% said Thursday its second-quarter net income fell to $234 million, or $1.96 a share from $631 million, or $4.96 a share in the year-ago quarter. Adjusted profit in the latest quarter totaled $2.36 a share.
- 07/21/2022
|
5 Dividend-Paying Stocks to Buy Ahead of Earnings Next Week
- Five dividend-paying companies will report second-quarter 2022 earnings results next week. These are: HAL, FNB, DGX, SLB and NEP.
- 07/15/2022
|
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/14/2022
|
Quest Diagnostics to launch monkeypox test in August
- Quest Diagnostics Inc. DGX, -1.38% said Wednesday that it developed a monkeypox test that it plans to launch in August. The PCR test, which is administered by a physician, can detect monkeypox and also differentiate that virus from other non-variola orthopoxviruses, the company said.
- 07/13/2022
|
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
- Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
- 07/11/2022
|
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
- Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
- 07/01/2022
|
Quest Diagnostics to Release Second Quarter 2022 Financial Results on July 21, 2022
- SECAUCUS, N.J. , June 24, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2022 financial results on Thursday, July 21, 2022, before the market opens.
- 06/24/2022
|
7 Undervalued Large-Cap Stocks to Buy Before Wall Street Catches On
- Even if the market has not yet reached the point of bottoming-out, these seven undervalued large-cap stocks are worth a look. The post 7 Undervalued Large-Cap Stocks to Buy Before Wall Street Catches On appeared first on InvestorPlace.
- 06/23/2022
|
Quest Diagnostics: Not Appealing Yet, Despite The Downturn
- Quest Diagnostics is a company I've been covering for a number of years, and one I wished I'd invested deeper in during the COVID-19 crash. We might be in for an opportunity to load up on a quality company like DGX - at a bit of a discount as well.
- 06/22/2022
|
Quest Diagnostic Stock is Ready to Move Higher
- Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been performing relatively stronger than the benchmark indices down only (-20%) on the year.
- 06/21/2022
|
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
- Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
- 06/15/2022
|
5 Stocks To Watch For June 11, 2022
- Some of the stocks that may grab investor focus today are: UP Fintech Holding Limited (NASDAQ: TIGR) is projected to report earnings results for the first quarter before the opening bell today. UP Fintech shares gained 3.9% to $5.30 in the after-hours trading session.
- 06/10/2022
|
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
- Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.
- 06/06/2022
|
Quest Diagnostics (DGX) Just Reclaimed the 200-Day Moving Average
- Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
- 05/30/2022
|
Quest Diagnostics to Speak at the UBS 2022 Global Healthcare Conference
- SECAUCUS, N.J. , May 11, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the UBS 2022 Global Healthcare Conference.
- 05/11/2022
|
7 Defensive Dividend Healthcare Stocks to Buy Now
- As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.
- 05/06/2022
|
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
- Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.
- 05/03/2022
|
Quest Diagnostics Incorporated's (DGX) CEO Steve Rusckowski on Q1 2022 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2022 Earnings Conference Call April 21, 2022 8:30 AM ET Company Participants Shawn Bevec - Vice President, Investor Relations Steve Rusckowski - Chairman and Chief Executive Officer and President Jim Davis - Chief Executive Officer-Elect Mark Guinan - Chief Financial Officer Conference Call Participants Ricky Goldwasser - Morgan Stanley Patrick Donnelly - Citi A.J. Rice - Credit Suisse Pito Chickering - Deutsche Bank Kevin Caliendo - UBS Jack Meehan - Nephron Research Brian Tanquilut - Jefferies Derik de Bruin - Bank of America Ann Hynes - Mizuho Securities Rachel Vatnsdal - J.P.
- 04/21/2022
|
Quest Diagnostics (DGX) Beats Q1 Earnings Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.65% and 1.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/21/2022
|
Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?
- Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/19/2022
|
Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business
- Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.
- 04/18/2022
|
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/14/2022
|
Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal
- Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.
- 04/06/2022
|
A Wake-Up Call for Bargain Hunters
- For bargain hunters, every stock market cloud has a silver lining. After a rough first quarter, dozens of stocks have descended to what I consider attractive levels.
- 04/04/2022
|
6 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.
- 03/31/2022
|
IHF: A Standout Performer With Strong Future Growth Prospects
- IHF: A Standout Performer With Strong Future Growth Prospects
- 03/30/2022
|
Quest Diagnostics to Release First Quarter 2022 Financial Results on April 21, 2022
- SECAUCUS, N.J. , March 30, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2022 financial results on Thursday, April 21, 2022, before the market opens.
- 03/30/2022
|
Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays
- According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.
- 03/24/2022
|
7 Healthcare Stocks to Buy for the Long Term
- When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. The post 7 Healthcare Stocks to Buy for the Long Term appeared first on InvestorPlace.
- 03/21/2022
|
Is Quest Diagnostics (DGX) a Good Stock for Value Investors?
- Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
- 03/11/2022
|
Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe
- Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.
- 03/09/2022
|
Analyst: Quest Diagnostics Stock Has a Tough Road Ahead
- Quest Diagnostics Inc (NYSE:DGX) stock is flat this morning, last seen 0.1% higher to trade at $130.71, after UBS downgraded the medical lab operator's shares to "neutral" from "buy.
- 02/23/2022
|
10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends
- If any investor has stood the test of time, it is Warren Buffett, and with good reason.
- 02/14/2022
|
3 Companies to Watch for the At-Home Diagnostics Boom
- Companies that provide at-home diagnostic testing kits weren't on many investors' radars before the Covid-19 pandemic. However, many people have wished at least once in their lives that they could order specific lab tests without having to make a trip to the doctor's office.
- 02/04/2022
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q4 2021 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q4 2021 Results - Earnings Call Transcript
- 02/03/2022
|
Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down
- Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.
- 02/03/2022
|
Quest Diagnostics (DGX) Lags Q4 Earnings Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2022
|
Quest Diagnostics net income falls, but revenue beats analyst estimate
- Quest Diagnostics Inc. DGX, +0.50% said Thursday its fourth-quarter net income fell to $390 million or $3.12 a share, from $579 million or $4.21 a share in the year-ago quarter. The blood testing company's adjusted net income dropped to $3.33 a share from $4.48 a share.
- 02/03/2022
|
Is a Surprise Coming for Quest Diagnostics (DGX) This Earnings Season?
- Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/02/2022
|
Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe
- Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.
- 01/31/2022
|
Quest to sell 50 tests directly to consumers through Walmart's website
- Shares of Quest Diagnostics Inc. DGX, -0.17% gained 1.0% in premarket trading on Monday after it said it will sell 50 common laboratory tests to consumers on Walmart Inc.'s WMT, +1.24% website. Consumers can buy tests to learn their blood type or iron levels, screen for drugs, and check their COVID-19 status, among other options.
- 01/31/2022
|
What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?
- In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.
- 01/27/2022
|
Here's Why You Should Add Quest Diagnostics (DGX) Stock Now
- Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.
- 01/26/2022
|
7 Undervalued Stocks That Won't Stay That Way for Long
- With growing concerns about stability inducing significant fear, contrarians may have an opportunity with undervalued stocks. The post 7 Undervalued Stocks That Won't Stay That Way for Long appeared first on InvestorPlace.
- 01/25/2022
|
Quest Diagnostics: Last Stock Standing On My Quality Plus Value Screen
- Duopoly lab operator Quest Diagnostics was the only stock to meet each parameter of my stock picking checklist for fundamentals, value, and risk. The stock's price accelerated at the beginning of the coronavirus pandemic thanks to near-sighted investors who anticipated tailwinds for diagnostic lab testing.
- 01/25/2022
|
Down 17.9% in 4 Weeks, Here's Why Quest Diagnostics (DGX) Looks Ripe for a Turnaround
- Quest Diagnostics (DGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/21/2022
|
Will Quest Diagnostics Stock Rebound After A Large 19% Fall In A Month?
- The stock price of Quest Diagnostics, one of the largest U.S. diagnostics chains, has seen a fall of 15% over the last twenty-one trading days, while it is up 5% over the last week. The recent fall came despite the company's preliminary results that were comfortably above the street estimates.
- 01/20/2022
|
Quest Diagnostics (DGX) Expands Extended Care With New Buyout
- This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.
- 01/19/2022
|
Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results
- Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.
- 01/13/2022
|
Why Quest Diagnostics Fell Nearly 7% Today
- The company's preliminary Q4 results topped analyst expectations, but investors were likely expecting better performance.
- 01/12/2022
|
Quest Diagnostics raises profit forecast on COVID testing surge
- Quest said it performed over 120,000 PCR tests per day in the last couple of weeks of 2021, and over 150,000 tests a day at the beginning of this year.
- 01/12/2022
|
Quest Diagnostics Stock Falls As FY22 EPS Outlook Lags Consensus
- Quest Diagnostics Inc (NYSE: DGX) expects Q4 sales of $2.74 billion, a decrease of 9% Y/Y, beating the consensus of $2.54 billion. The company noted preliminary Q4 results reflect higher than expected demand for COVID-19 testing services, while base testing volumes remained steady and consistent with the previous outlook.
- 01/12/2022
|
Quest Diagnostics offers above-consensus guidance for Q4, raises 2022 outlook
- Quest Diagnostics Inc. DGX, -1.08% offered guidance for the fourth quarter and full year on Wednesday that exceeded Wall Street estimates, driven by demand for COVID-19 testing services. The company is now expecting per-share earnings of $3.12 and adjusted EPS of $3.33, ahead of the $3.07 FactSet consensus.
- 01/12/2022
|
Quest Diagnostics to Release Fourth Quarter and Full Year 2021 Financial Results on February 3, 2022
- SECAUCUS, N.J., Jan. 11, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2021 financial results on Thursday, February 3, 2022, before the market opens.
- 01/11/2022
|
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
- Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/07/2022
|
Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain
- Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.
- 01/04/2022
|
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
- Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
- 01/03/2022
|
Quest Diagnostics (DGX) is an Incredible Growth Stock: 3 Reasons Why
- Quest Diagnostics (DGX) could produce exceptional returns because of its solid growth attributes.
- 12/27/2021
|
Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?
- Here is how Quest Diagnostics (DGX) and LabCorp (LH) have performed compared to their sector so far this year.
- 12/27/2021
|
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
- Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
- 12/23/2021
|
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
- Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).
- 12/15/2021
|
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
- Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
- 12/03/2021
|
Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks
- According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.
- 11/26/2021
|
7 Stocks to Buy as America Lifts Its Travel Ban
- With the Biden administration making the move to open U.S. land borders with Canada and Mexico, these stocks to buy can get a boost. The post 7 Stocks to Buy as America Lifts Its Travel Ban appeared first on InvestorPlace.
- 11/19/2021
|
Why This Diagnostics Stock Is a Buy
- Quest Diagnostics beat analysts' estimates in the third quarter and raised its guidance for this year again.
- 11/18/2021
|
4 Medical Products Stocks Poised to Beat This Earnings Season
- Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
- 10/28/2021
|
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/26/2021
|
5 Value Stocks Based on Discounted PEG to Buy Now
- Here are five stocks, OLN, DGX, EQNR, TECK, and GS that qualify the screening.
- 10/26/2021
|
Quest Diagnostics (DGX) Sees Hammer Chart Pattern: Time to Buy?
- Quest Diagnostics (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.
- 10/26/2021
|
Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up
- Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
- 10/21/2021
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q3 2021 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q3 2021 Results - Earnings Call Transcript
- 10/21/2021
|
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 33.78% and 12.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/21/2021
|
Quest Diagnostics net income falls; hikes 2021 outlook
- Quest Diagnostics Inc. DGX, +0.78% said Thursday its third-quarter net income fell to $505 million, or $4.02 a share, from $568 million, or $4.14 a share in the year-ago quarter. Adjusted earnings fell to $3.96 a share from $4.31 a share.
- 10/21/2021
|
Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company's Verzenio® (abemaciclib), a CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
- SECAUCUS, N.J., Oct. 18, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic.
- 10/18/2021
|
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
- Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
- 10/15/2021
|
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?
- Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/14/2021
|
COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings
- In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.
- 10/14/2021
|
Quest Diagnostics CEO on the future of Covid testing
- Meg Tirrell joins The Exchange with Quest Diagnostics CEO Steve Rusckowski to discuss the future of Covid testing. As the flu and cold seasons return, Rusckowski says, he expects more people will turn up to Covid testing when they present symptoms that are similar to those of Covid, the flu and the common cold.
- 10/12/2021
|
Quest Diagnostics Debuts Next-Generation Lab Facility in Clifton, NJ
- SECAUCUS, N.J., Oct. 12, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, has completed its integration of Northeast regional operations to its new 250,000 sq.
- 10/12/2021
|
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
- Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.
- 10/11/2021
|
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/08/2021
|
Quest Diagnostics To Release Third Quarter 2021 Financial Results On October 21
- SECAUCUS, N.J., Sept. 29, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2021 financial results on Thursday, October 21, 2021, before the market opens.
- 09/29/2021
|
Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers
- Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).
- 09/29/2021
|
Here's Why You Should Invest in Quest Diagnostics (DGX) Now
- Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.
- 09/29/2021
|
The Delta Variant Has Made Quest Diagnostics Indispensable
- On the back of steady demand for COVID-19 testing, Quest Diagnostics bumped up its guidance for this year.
- 09/29/2021
|
3 Top Stocks From the Buoyant Outpatient Home Health Industry
- Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. EHC, RDNT and USPH are well-poised to gain from the prospects.
- 09/28/2021
|
Over Half of U.S. Children Have Detectable Levels of Lead in their Blood, Finds Quest Diagnostics Health Trends® Study Published in JAMA Pediatrics
- SECAUCUS, N.J., Sept. 28, 2021 /PRNewswire/ -- One in two (50.5%) American children under six years of age tested have detectable levels of lead, a toxic metal, in their blood, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) released today and published in JAMA Pediatrics.
- 09/28/2021
|
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 09/22/2021
|
Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months
- The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).
- 09/20/2021
|
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
- Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
- 09/14/2021
|
Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge
- Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.
- 09/10/2021
|
Quest Diagnostics Updates 2021 Outlook On Surging Demand Of COVID-19 Tests
- Since Quest Diagnostics Incorporated (NYSE: DGX) reported its Q2 FY21 financial results, COVID-19 molecular testing volumes were stronger than anticipated through the end of August. Related Content: Quest Q2 Earnings Ahead Of Expectation On Recovery Of Non-COVID Business, Issues Mixed FY21 Guidance.
- 09/09/2021
|
Quest Diagnostics hikes financial estimates on Delta variant testing boost
- Quest Diagnostics Inc. DGX, +1.58% on Thursday raised its 2021 financial outlook on the heels of increased testing activity for Covid-19. Since the company issued its last projections on July 22, it's seen stronger-than-expected molecular testing volumes through the end of August.
- 09/09/2021
|
Quest Diagnostics Updates Outlook For Full Year 2021
- SECAUCUS, N.J., Sept. 9, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today updated its financial outlook for full year 2021.
- 09/09/2021
|
Quest Diagnostics to Speak at the Morgan Stanley 19th Annual Global Healthcare Conference
- SECAUCUS, N.J., Aug. 30, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 19th Annual Global Healthcare Conference.
- 08/30/2021
|
Quest Diagnostics: A Leader In Its Industry, With COVID Tailwinds Driving Revenue
- Quest is a member of a duopoly. As such, it has a strong pricing advantage related to scale.
- 08/27/2021
|
Quest Diagnostics Elects Tracey C. Doi to Board of Directors
- SECAUCUS, N.J., Aug. 17, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Ms.
- 08/17/2021
|
Quest Diagnostics Declares Quarterly Cash Dividend
- SECAUCUS, N.J., Aug. 16, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.62 per share, payable on October 20, 2021 to shareholders of record of Quest Diagnostics common stock on October 5, 2021.
- 08/16/2021
|
Quest Diagnostics (DGX), eMed Deal to Boost BinaxNOW Sales
- Under the collaboration, eMed's Certified Guide will supervise Quest Diagnostics' (DGX) BinaxNOW home testing process virtually.
- 08/12/2021
|
Quest Diagnostics, eMed Team Up To Offer COVID-19 Rapid Antigen Testing At Workplaces
- Telehealth company eMed and Quest Diagnostics Inc (NYSE: DGX) have collaborated for clinician-guided rapid antigen testing for COVID-19 in workplaces. Through the collaboration, the two companies will leverage the BinaxNOW COVID-19 Ag Card Home Test, a self-administered nasal swab antigen test that provides results in 15 minutes.
- 08/11/2021
|
Is This Diagnostics Company a Buy After Blowing Away Earnings Estimates?
- Quest Diagnostics was the beneficiary of a faster than expected recovery in its base business in the second quarter.
- 07/30/2021
|
Quest Diagnostics CEO on Covid testing: Majority are delta variants
- Steve Rusckowski, Quest Diagnostics chairman and CEO, joins 'Closing Bell' to discuss the company's quarterly earnings, how much of the business remains coronavirus-related and the uptick in testing demand as delta variant cases rise.
- 07/28/2021
|
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
- The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
- 07/27/2021
|
Quest Diagnostics seeing a rise in Covid tests as delta variant spreads, CEO says
- Quest Diagnostics CEO Steve Rusckowski told CNBC the company is seeing an increase in Covid-19 tests, with the majority of positive results this week identified as the delta variant.
- 07/22/2021
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2021 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2021 Results - Earnings Call Transcript
- 07/22/2021
|
Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong
- According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.
- 07/22/2021
|
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.80% and 6.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/22/2021
|
Quest Diagnostics adjusted profit more than doubles, beat expectations
- Quest Diagnostics Inc. reported Thursday second-quarter adjusted profit that more than doubled to beat expectations, as revenue also topped forecasts, as the recovery in the lab results and diagnostics company cited a faster-than-expected recovery in its base business. Net income rose to $631 million, or $4.96 a share, from $185 million, or $1.36 a share, in the year-ago period.
- 07/22/2021
|
Quest Diagnostics Reports Second Quarter 2021 Financial Results; Establishes Full Year 2021 Outlook
- SECAUCUS, N.J., July 22, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2021.
- 07/22/2021
|
Quest Diagnostics's Earnings: A Preview
- Quest Diagnostics (NYSE:DGX) will be releasing its next round of earnings this Thursday, July 22. For all of the relevant information, here is your guide for Thursday's Q2 earnings announcement.
- 07/21/2021
|
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
- Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
- 07/21/2021
|
Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings
- Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.
- 07/19/2021
|
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?
- Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/15/2021
|
Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Fourth Consecutive Year
- SECAUCUS, N.J., July 14, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2021 Disability Equality Index® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).
- 07/14/2021
|
Quest Diagnostics Stock is Worth a Flier Before Earnings
- Quest Diagnostics Incorporated (NYSE:DGX) offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, and drugs.
- 07/13/2021
|
Quest Diagnostics and Local Chapters of Feeding America, Big Brothers Big Sisters and Federally Qualified Health Centers Team Up to Address the Hidden Pandemic's Impact on Underserved Communities
- TAMPA, Fla., July 12, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services today announced the Tackle Your Testing program to address the health disparities exacerbated by delayed treatment or diagnosis during the COVID-19 pandemic.
- 07/12/2021
|
Quest Diagnostics To Release Second Quarter 2021 Financial Results On July 22
- SECAUCUS, N.J., July 6, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2021 financial results on Thursday, July 22, 2021, before the market opens.
- 07/06/2021
|
ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
- ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
- 06/28/2021
|
Quest Diagnostics (DGX) Unveils Corporate Responsibility Report
- Per Quest Diagnostics' (DGX) 2020 Corporate Responsibility Report, it has expanded COVID-19 capacity throughout the year, performing 30 million COVID-19 molecular tests and serology tests.
- 06/23/2021
|
Biocept partners with Quest Diagnostics to provide its Target Selector NGS-based liquid biopsy testing for lung cancer
- Biocept Inc (NASDAQ:BIOC) (FRA:B003) has announced a collaboration with Quest Diagnostics Inc (NYSE:DGX) (FRA:QDI) to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel. Biocept said both companies expect the service to be available to Quest's providers and patients in the fourth quarter of 2021.
- 06/22/2021
|
Quest Diagnostics Releases Annual Corporate Responsibility Report
- SECAUCUS, N.J., June 21, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today released the Annual Corporate Responsibility Report for 2020.
- 06/21/2021
|
2 Incredibly Cheap Healthcare Stocks
- These companies dominate a vital medical industry niche, and their valuations are near their all-time lows.
- 06/18/2021
|
3 Medical Diagnostics Stocks in Focus on Long-Term Potential
- MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.
- 06/07/2021
|
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
- 3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
- 06/04/2021
|
Quest Diagnostics: A Demographic Play At A Reasonable Price
- Quest Diagnostics was one of the clear beneficiaries of the pandemic.
- 06/03/2021
|
Quest Diagnostics (DGX) Buys Outreach Lab, Widens Midwest Base
- Mercy's outreach laboratory services are set to get integrated into Quest Diagnostics' (DGX) full-service laboratory in Lenexa, KS.
- 06/02/2021
|
Quest Diagnostics Completes Acquisition of Mercy's Outreach Laboratory Services Business
- SECAUCUS, N.J. and ST. LOUIS, June 1, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX) and Mercy today announced that Quest has completed its previously announced acquisition of the outreach laboratory services business of Mercy in an all-cash asset transaction.
- 06/01/2021
|
Marijuana Workforce Drug Test Positivity Continues Double-Digit Increases to Keep Overall Drug Positivity Rates at Historically High Levels, Finds Latest Quest Diagnostics Drug Testing Index™ Analysis
- SECAUCUS, N.J., May 26, 2021 /PRNewswire/ -- The COVID-19 pandemic did not dampen workforce drug testing positivity for marijuana, which continued to increase last year in the general U.S. workforce, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
- 05/26/2021
|
Laboratory Corp: A Solid Margin of Safety
- Like many other diagnostics and drug development companies, Laboratory Corp. of America Holdings ( LH , Financial) saw its base business decline as Covid-19 took hold. Fewer patients sought routine medical care and many clinical trials were suspended, leading to a decline in its two streams of revenue.
- 05/25/2021
|
3 Stocks to Bank on Rebounding Outpatient Home Health Industry
- 3 Stocks to Bank on Rebounding Outpatient Home Health Industry
- 05/25/2021
|
Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe
- Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).
- 05/25/2021
|
Quest Diagnostics and Paige Form Collaboration to Advance AI-generated Pathology Insights to Improve Cancer Diagnosis and Care
- SECAUCUS, N.J. and NEW YORK, May 25, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX) and Paige today announced a collaboration designed to unlock the potential of artificial intelligence (AI) to improve and speed the diagnosis of cancer and other diseases that rely on pathologic assessment.
- 05/25/2021
|
Social & Health Research Center and Quest Diagnostics Team Up to Address Childhood Hunger and Obesity Exacerbated by COVID-19 in Underserved Communities
- SAN ANTONIO and SECAUCUS, N.J., May 24, 2021 /PRNewswire/ -- Childhood obesity has disproportionately affected Hispanic and Black communities as a result of negative social determinants of health for years.
- 05/24/2021
|
Quest Diagnostics Declares Quarterly Cash Dividend
- SECAUCUS, N.J., May 20, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.62 per share, payable on July 21, 2021 to shareholders of record of Quest Diagnostics common stock on July 7, 2021.
- 05/20/2021
|
Quest Diagnostics To Speak At The Jefferies Virtual Healthcare Conference
- SECAUCUS, N.J., May 19, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Virtual Healthcare Conference.
- 05/19/2021
|
3 Stocks That Could Represent Bargain Opportunities
- If you are looking for bargain opportunities among U.S.-listed equities, then you may want to consider the following three stocks, as they meet the criteria just listed below:
- 05/18/2021
|
IYH: Healthcare Dashboard For May
- IYH: Healthcare Dashboard For May
- 05/17/2021
|
Quest Diagnostics (DGX) Expands COVID-19 Test Eligibility
- This zero out-of-pocket option applies to Quest Diagnostics' (DGX) molecular laboratory (PCR/NAAT) as well as rapid antigen testing.
- 05/14/2021
|
Quest Diagnostics Expands Eligibility for $0 Out-of-Pocket COVID-19 Testing Through QuestDirect™ To Assist in Combatting the Pandemic and Help Support Safer Travel, Events and Gatherings Nationwide
- SECAUCUS, N.J., May 11, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today unveiled several new enhancements to its COVID-19 testing services, with the goal to help combat COVID-19 while empowering more individuals and families to resume "back to life" activities with greater safety this spring, summer and beyond.
- 05/11/2021
|
CIC Health and Quest Diagnostics Collaborate to Help Schools, Camps Open Safely Nationwide
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--CIC Health and Quest Diagnostics announced a collaboration that will help more schools safely return to in-person learning.
- 05/10/2021
|
Quest Diagnostics To Speak At BofA Securities 2021 Virtual Healthcare Conference
- SECAUCUS, N.J., April 27, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the BofA Securities 2021 Virtual Healthcare Conference.
- 04/27/2021
|
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
- The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
- 04/27/2021
|
7 Healthcare Stocks for a Reopening World
- The stock market is at all-time highs, and the world is starting to reopen. But these healthcare stocks have more growth opportunities ahead.
- 04/26/2021
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q1 2021 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q1 2021 Results - Earnings Call Transcript
- 04/22/2021
|
Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong
- The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.
- 04/22/2021
|
Quest Diagnostics (DGX) Q1 Earnings Lag Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.27% and 1.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/22/2021
|
Recap: Quest Diagnostics Q1 Earnings
- Shares of Quest Diagnostics (NYSE:DGX) rose 0.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 300.00% year over year to $3.76, which beat the estimate of $3.71.
- 04/22/2021
|
Quest Diagnostics Reports First Quarter 2021 Financial Results; Announces Plan for $1.5 Billion Accelerated Share Repurchase
- SECAUCUS, N.J., April 22, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2021.
- 04/22/2021
|
Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings
- Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.
- 04/19/2021
|
Quest Diagnostics and Blueprint Genetics to Present New Insights from Genetic Testing at the 2021 Annual American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
- SECAUCUS, N.J. and HELSINKI, Finland, April 13, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Blueprint Genetics announced today that they will present results of 10 studies at the virtual 2021 American College of Medical Genetics and Genomics (ACMG) Annual Meeting, to be held April 13–16, 2021.
- 04/13/2021
|
5 Stocks Paying High Dividend Yields
- As of April 9, the GuruFocus All-in-One Screener, a Premium feature, found that the following companies have low price-earnings ratios and high dividend yields.
- 04/09/2021
|
Quest Diagnostics To Release First Quarter 2021 Financial Results On April 22
- SECAUCUS, N.J., April 7, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2021 financial results on Thursday, April 22, 2021, before the market opens.
- 04/07/2021
|
Quest Diagnostics (DGX) Rides on Test Sales Amid Volume Woe
- Quest Diagnostics (DGX) enters into an agreement with the CDC to provide genomic sequencing to identify new mutations in and patterns of transmission of SARS-CoV-2.
- 04/06/2021
|
Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions
- Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.
- 04/05/2021
|
7 Upcoming Dividend Increases To Start Q2
- 7 Upcoming Dividend Increases To Start Q2
- 04/01/2021
|
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
- Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
- 04/01/2021
|
Quest Diagnostics Sells Ownership Interest in Q² Solutions to IQVIA
- SECAUCUS, N.J. and RESEARCH TRIANGLE PARK, N.C.
- 04/01/2021
|
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
- MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
- 03/19/2021
|
Quest Diagnostics: The Safest Dividend Is One That's Just Been Raised
- Quest Diagnostics has seen a strong cash windfall from COVID-19 testing, and recently expanded its buyback program. I see future growth potential from industry consolidation, and from expanded partnerships with hospitals for inpatient testing.
- 03/19/2021
|
3 Stocks Trading Below the Peter Lynch Earnings Line
- Value investors may be interested in the following three stocks since their share prices are trading below their respective Peter Lynch earnings lines, indicating they could be undervalued. Sell-side analysts on Wall Street have also issued positive ratings for these companies.
- 03/17/2021
|
Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care
- Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.
- 03/16/2021
|
Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test
- SECAUCUS, N.J. and HELSINKI, March 15, 2021 /PRNewswire/ -- Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for Zora's patented ceramide-analysis technology.
- 03/15/2021
|
5 Undervalued Stocks With Profitable Business
- According to the GuruFocus discounted cash flow calculator as of March 14, the following companies have a high margin of safety and have grown their margins over a 10-year period.
- 03/14/2021
|
Quest Diagnostics Updates Strategic Growth Drivers and Provides Long-Term Outlook at 2021 Virtual Investor Day
- SECAUCUS, N.J., March 11, 2021 /PRNewswire/ -- At a virtual meeting with analysts and investors at its Investor Day, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will report on progress made on the company's two-point strategy to accelerate growth and drive operational excellence, and provide a new long-term financial outlook.
- 03/11/2021
|
Quest Diagnostics and Mercy Broaden Access to Innovative, Convenient Lab Services in the Midwest
- SECAUCUS, N.J., and ST. LOUIS, March 8, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Mercy, one of the nation's most highly integrated, multi-state health care systems, today announced a definitive agreement for Quest to...
- 03/08/2021
|
Top 5 4th-Quarter Trades of Chris Davis' Firm
- Davis Select Advisors recently released its fourth-quarter 2020 portfolio update. Among the changes made during the quarter, the firm disclosed a new position in Viatris Inc. (NASDAQ:VTRS), a position boost in Cigna Corp. (NYSE:CI) and reductions in its holdings in Facebook Inc. (NASDAQ:FB), Quest Diagnostics Inc. (NYSE:DGX) and Alphabet Inc. (NASDAQ:GOOGL)(NASDAQ:GOOG).
- 02/26/2021
|
Quest Diagnostics Introduces New COVID-19 Semi-quantitative Serology Test Service
- SECAUCUS, N.J., Feb. 24, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new COVID-19 testing service that aids in providing insight into an individual's immune response as a result of a recent or...
- 02/24/2021
|
GRAIL and Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
- MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced an agreement with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, to provide phlebotomy services to support Galleri™, GRAIL's multi-cancer early detection blood test. Quest Diagnostics maintains approximately 2,200 patient service centers and, through its ExamOne business, 5,000 mobile phlebotomists with exp
- 02/23/2021
|
Quest Diagnostics to Host Virtual Investor Day On March 11, 2021
- SECAUCUS, N.J., Feb. 9, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will host a virtual Investor Day for institutional investors and financial analysts on Thursday, March 11, 2021 at 9:00 a.m. ET. During the event,...
- 02/09/2021
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q4 2020 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q4 2020 Results - Earnings Call Transcript
- 02/04/2021
|
Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows
- Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.
- 02/04/2021
|
Quest Diagnostics (DGX) Surpasses Q4 Earnings and Revenue Estimates
- Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.67% and 2.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/04/2021
|
Quest Diagnostics increases quarterly dividend, boosts share buyback by $1 billion
- Quest Diagnostics Inc. said Thursday its board has approved a 10.7% increase in its quarterly dividend to 62 cents a share. The new dividend will be payable April 21 to shareholders of record as of April 7.
- 02/04/2021
|
Quest Diagnostics Increases Dividend 10.7% To $0.62 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization
- SECAUCUS, N.J., Feb. 4, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the Company's Board of Directors has authorized a 10.7% increase in its quarterly dividend from $0.56 to $0.62 per...
- 02/04/2021
|
Quest Diagnostics Named One of 2021 "World's Most Admired Companies" by FORTUNE Magazine for Seventh Consecutive Year
- SECAUCUS, N.J., Feb. 1, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2021 for the seventh consecutive year. "We are...
- 02/01/2021
|
Why Quest Diagnostics Stock Is Jumping Today
- An analyst raised his price target for the stock.
- 01/29/2021
|
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
- 3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
- 01/28/2021
|
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
- Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
- 01/28/2021
|
4 MedTech Underperformers Poised for a Turnaround in 2021
- Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
- 01/21/2021
|
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
- 3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
- 01/20/2021
|
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
- The Department of Health and Human Services (HHS) promises over $22 billion of funding.
- 01/19/2021
|
Quest Diagnostics (DGX) COVID-19 Test Sales Solid, Volume Dull
- Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.
- 01/18/2021
|
Quest Diagnostics Granted CDC Contract to Sequence COVID-19 Gene Variants to Aid Public Health Response to COVID-19
- SECAUCUS, N.J., Jan. 18, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to provide genomic sequencing to...
- 01/18/2021
|
Quest Diagnostics To Release Fourth Quarter And Full Year 2020 Financial Results On February 4
- SECAUCUS, N.J., Jan. 13, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2020 results on Thursday, February 4, 2021, before the market opens. It...
- 01/13/2021
|
Testing Space in Focus Again Thanks to New Wave of Coronavirus
- The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
- 01/13/2021
|
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
- In the latest trading session, Quest Diagnostics (DGX) closed at $123.63, marking a +0.54% move from the previous day.
- 01/11/2021
|
Quest Diagnostics (DGX) Gains But Lags Market: What You Should Know
- Quest Diagnostics (DGX) closed at $121.74 in the latest trading session, marking a +0.51% move from the prior day.
- 01/05/2021
|
Quest Diagnostics: A COVID-19 Beneficiary
- Quest Diagnostics has effectively captured 24% of a $28Bn market, while earning the loyalty of 11Mn customers digitally by providing low cost, high quality services at one-eighth the cost. The $2.4Bn COVID-19 revenue boost in 2020 and 2021 is being underappreciated by the Street (4.5% 6-month return).
- 01/04/2021
|
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
- Is (DGX) Outperforming Other Medical Stocks This Year?
- 01/01/2021
|
Quest Diagnostics (DGX) Sees Hammer Chart Pattern: Time to Buy?
- Quest Diagnostics Incorporated (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.
- 12/30/2020
|
Quest Diagnostics (DGX) Stock Moves -0.08%: What You Should Know
- In the latest trading session, Quest Diagnostics (DGX) closed at $118.40, marking a -0.08% move from the previous day.
- 12/29/2020
|
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
- Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
- 12/28/2020
|
DGX vs. EHC: Which Stock Is the Better Value Option?
- DGX vs. EHC: Which Stock Is the Better Value Option?
- 12/22/2020
|
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/22/2020
|
Hackensack Meridian Health and Quest Diagnostics Partner to Deliver High-Value, Innovative Laboratory Services
- SECAUCUS, N.J. and NUTLEY, N.J., Dec. 22, 2020 /PRNewswire/ -- Hackensack Meridian Health (HMH), the largest, most comprehensive and truly integrated health care network in New Jersey, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, are...
- 12/22/2020
|
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
- In the latest trading session, Quest Diagnostics (DGX) closed at $120.85, marking a +0.41% move from the previous day.
- 12/21/2020
|
Quest Diagnostics and The Commons Project to Deliver Convenient Access to Lab Data -- Including COVID-19 Test Results -- Through the CommonHealth App
- SECAUCUS, N.J., Dec. 17, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and The Commons Project, a non-profit public trust dedicated to building and operating global digital platforms and services for public good, today...
- 12/17/2020
|
Quest Diagnostics stock rises after full-year profit and revenue outlook raised
- Shares of Quest Diagnostics Inc. rose 0.7% in premarket trading Wednesday, after the clinical lab testing company raised its full-year profit, revenue and cash flow outlook, as COVID-19 molecular testing volumes have been "significantly higher" than what was expected in late October. The company said it now expects 2020 adjusted earnings per share of "at least" $10.75, compared with its previous guidance range of $9.00 to $10.00 and the FactSet consensus of $10.01.
- 12/16/2020
|
Quest Diagnostics Raises Outlook for Full Year 2020
- SECAUCUS, N.J., Dec. 16, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today raised its financial outlook for full year 2020. Since the company reported its financial performance for the third quarter of...
- 12/16/2020
|
New Coronavirus Tests Have These Diagnostics Companies Recalibrating
- The COVID-19 testing landscape is changing. Will that sap the growth of the incumbent leaders?
- 12/05/2020
|
Quest Diagnostics (DGX) Down 1.2% Since Last Earnings Report: Can It Rebound?
- Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
- 11/21/2020
|
Quest Diagnostics Declares Quarterly Cash Dividend
- SECAUCUS, N.J., Nov. 18, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on February 3, 2021 to shareholders of...
- 11/18/2020
|
Cramer on four coronavirus testing stocks worth owning
- "I bet the testing stocks have a lot more room to run," the "Mad Money" host said.
- 11/05/2020
|
Quidel, Abbott, Quest: Testing Stocks To Watch As Covid-19 Cases Surge
- Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly outperforming the S&P 500 which has gained about 3% over the same period. Covid-19 testing stocks could be.
- 11/04/2020
|
7 Top Stocks to Buy for November
- As we near the end of 2020, it's time to safeguard your portfolio before we enter the new year. Here are the top stocks to buy in November.
- 11/03/2020
|
Quest Diagnostics To Speak At The Credit Suisse 29th Annual Virtual Healthcare Conference
- SECAUCUS, N.J., Nov. 3, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Credit Suisse 29th Annual Virtual Healthcare Conference. Steve Rusckowski, Chairman,...
- 11/03/2020
|
2 Hot Coronavirus Stocks That Just Beat Earnings Expectations
- Their numbers are set to keep rising during the pandemic.
- 11/02/2020
|
Stock Upgrades: Quest Diagnostics Among Companies Shows Rising Strength In Coronavirus Market
- Quest Diagnostics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating The post Stock Upgrades: Quest Diagnostics Among Companies Shows Rising Strength In Coronavirus Market appeared first on Investor's Business Daily.
- 10/28/2020
|
Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond
- SECAUCUS, N.J., Oct. 27, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help...
- 10/27/2020
|
Were Hedge Funds Right About Crowding Into Quest Diagnostics (DGX)?
- In this article we will check out the progression of hedge fund sentiment towards Quest Diagnostics Incorporated (NYSE:DGX) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.
- 10/26/2020
|
Thermo Fisher Should Buy Quest To Fully Integrate Lab Testing
- A Thermo Fisher - Quest Diagnostics merger would have numerous cost synergy and sales growth possibilities.
- 09/09/2020
|
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2020 Update
- Glenview Capital Management's 13F portfolio value decreased from $3.68B to $3.63B this quarter. The number of positions decreased from 44 to 43.
- 09/04/2020
|
OPKO's Rayaldee Drug Could Be A Leading COVID-19 Treatment
- Yale's saliva-based coronavirus test funded by NBA gets emergency authorization from the FDA. Is BioReference at the front of the line to use this new test because of the assistance it has provided? Will Rayaldee prove to be an effective COVID-19 treatment?.
- 08/20/2020
|
Quest Diagnostics Declares Quarterly Cash Dividend
- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on October 21, 2020 to shareholders of record of Quest Diagnostics common stock on October 6, 2020.
- 08/18/2020
|
Quest Diagnostics Incorporated's (NYSE:DGX) Shares May Have Run Too Fast Too Soon
- Quest Diagnostics Incorporated's (NYSE:DGX) price-to-earnings (or "P/E") ratio of 21.5x might make it look like a sell...
- 08/18/2020
|
Quest Diagnostics Trims Covid-Test Turnaround to 1-2 Days
- Quest cut its coronavirus-test turnaround time to one or two days. The figure was two to three days a week ago and seven days last month.
- 08/18/2020
|
Quest Diagnostics says it cut coronavirus testing turnaround to one to two days, but warns it could slip
- A limited supply of the right kinds of Covid-19 tests has hampered the U.S. response to the coronavirus since the very beginning, public health specialists say.
- 08/18/2020
|
Delta partners with CVS Health for rapid COVID-19 tests
|
How Does Quest Diagnostics's Debt Look?
- Shares of Quest Diagnostics Inc. (NYSE: DGX) increased by 6.20% in the past three months. Before having a look at the importance of debt, let's look at how much debt Quest Diagnostics has.Quest Diagnostics's Debt Based on Quest Diagnostics's financial statement as of July 24, 2020, long-term debt is at $4.02 billion and current debt is at $555.00 million, amounting to $4.58 billion in total debt. Adjusted for $988.00 million in cash-equivalents, the company's net debt is at $3.59 billion.To understand the degree of financial leverage a company has, shareholders look at the debt ratio. Considering Quest Diagnostics's $12.99 billion in total assets, the debt-ratio is at 0.35. As a rule of thumb, a debt-ratio more than 1 indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. A debt ratio of 35% might be higher for one industry, whereas average for another.Why Shareholders Look At Debt? Debt is an important factor in the capital structure of a company, and can help it attain growth. Debt usually has a relatively lower financing cost than equity, which makes it an attractive option for executives.Interest-payment obligations can impact the cash-flow of the company. Equity owners can keep excess profit, generated from the debt capital, when companies use the debt capital for its business operations.See more from Benzinga * Benzinga's Top Upgrades, Downgrades For July 29, 2020 * Stocks That Hit 52-Week Highs On Thursday * Quest Diagnostics: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/17/2020
|
Anthem and Quest Diagnostics Form Strategic Relationship
- Anthem Inc. (NYSE: ANTM) and Quest Diagnostics (NYSE: DGX) have entered into a strategic relationship by collaborating on a variety of outcomes-based programs designed to create an improved health care experience for consumers and providers beginning August 1, 2020.
- 08/17/2020
|
Quest Diagnostics Releases Annual Environmental, Social & Governance Report
- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today released its Annual Environmental, Social & Governance Report for 2019.
- 08/12/2020
|
Global Food Allergen Testing Market 2020-2024: Breakdown by LC/MS, Immunoassay/ELISA, and PCR Technology - ResearchAndMarkets.com
|
Ariel Investments' John Rogers Shares Insight About Stocks, Racial Relations
- John Rogers, the first Black founder of a mutual fund complex, offers advice about investments and what this summer of agitation is telling Americans.
- 08/10/2020
|
Quest Diagnostics: A Steady Investment Opportunity Buoyed By Current Market Tailwinds (NYSE:DGX)
- Quest Diagnostics operates the world's largest clinical testing data-store and provides diagnostic services across the entire healthcare spectrum.
- 08/10/2020
|
Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q2 2020 Results - Earnings Call Transcript
- Oxford Immunotec Global PLC (NASDAQ:OXFD) Q1 2021 Earnings Conference Call August 04, 2020 08:00 AM ET Company Participants Matt McLaughlin - Chief Financial Officer Peter Wrighton-Smith - Chief Executive Officer Conference Call Participants Sung Ji Nam - BTIG Chris Lin - Cowen Presentation Operator Good morning, ladies and gentlemen, and welcome to the Oxford Immunotec Second Quarter 2020 Earnings Call.
- 08/09/2020
|
Becton Dickinson Earnings Top, But BDX Stock Falls On Weak Sales
- Becton Dickinson earnings beat views, but the coronavirus test maker missed on revenue and gave weak full-year guidance below expectations. Shares tumbled out of a buy zone early Thursday,
- 08/06/2020
|
$1.6 Billion Worldwide Specimen Validity Testing Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com
|
Pale Blue Portfolio Review, May 18-July 31: 17 Buys, 2 Sells, 15.45% Gains
- The Pale Blue Portfolio gained 15.45% between May 18 and July 31. I slightly adjusted my purchasing strategy in July.
- 08/04/2020
|
Oxford Immunotec Global PLC (OXFD) Q2 2020 Earnings Call Transcript
- It is now my pleasure to turn the call over to Matt McLaughlin, Chief Financial Officer. Good morning and thank you for joining us to review Oxford Immunotec's financial results for the second quarter of 2020. Any statements made during this call that are not statements of historical or current facts are intended to be forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- 08/04/2020
|
Quest Diagnostics Completes Acquisition of Mid America Clinical Laboratories, Now Provides Professional Lab Management for Nearly 30 Hospitals of Community Health Network and Ascension St. Vincent in Indiana
- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of its joint venture partners' interests in Mid America Clinical Laboratories ("MACL").
- 08/03/2020
|
Quest Diagnostics Launches Automated Next Generation Sequencing (NGS) Engine To Power AncestryHealth®
- A new innovation in advanced genetic sequencing automation from Quest Diagnostics (NYSE: DGX) will now enable individuals to access highly accurate genetic testing providing insights into inherited diseases including cancers of the breast, colon and other conditions through AncestryHealth®.
- 08/03/2020
|
Janney Montgomery Scott LLC Lowers Stock Holdings in Quest Diagnostics Inc (NYSE:DGX)
- Janney Montgomery Scott LLC decreased its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 31.3% during the second quarter, HoldingsChannel reports. The firm owned 13,666 shares of the medical research company’s stock after selling 6,232 shares during the period. Janney Montgomery Scott LLC’s holdings in Quest Diagnostics were worth $1,557,000 at the end of […]
- 08/03/2020
|
Ancestry® Launches AncestryHealth® Powered by Next Generation Sequencing (NGS)
- Ancestry®, the global leader in family history and consumer genomics, today announced the launch of AncestryHealth® powered by Next Generation Sequenc
- 08/03/2020
|
Covid-19 testing delays create a public health nightmare as schools and workplaces try to reopen
- Across the country, patients are reporting delays in getting their Covid-19 test results because of major supply shortages.
- 08/02/2020
|
Quest Diagnostics Inc (NYSE:DGX) Shares Purchased by CIBC Asset Management Inc
- CIBC Asset Management Inc boosted its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 2.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,394 shares of the medical research company’s stock after acquiring an additional 578 shares during the period. CIBC Asset […]
- 08/01/2020
|
Craving Healthcare: A Beginner's Guide And My 7 Picks
- The Healthcare sector has significantly outperformed the S&P 500 in the last decade and with lower volatility – the only sector to do so.
- 07/31/2020
|
Craving Healthcare: A Beginner's Guide And My 7 Picks
- The Healthcare sector has significantly outperformed the S&P500 in the last decade and with lower volatility – the only sector to do so.
- 07/31/2020
|
Quest Gets FDA Nod For Faster Covid-19 Testing; Analyst Flips To Buy Call
- Quest Diagnostics Inc. (DGX) announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for a new laboratory technique that speeds up COVID-19 molecular diagnostic testing capacity and provides faster test results.The diagnostic company said that the new lab method quickens the process of extracting viral RNA from specimens and is designed to help boost its daily capacity of COVID-19 molecular diagnostic tests for patients in the US.Currently Quest has the capacity to perform 135,000 COVID-19 molecular diagnostic tests a day. The new method is slated to add an additional 35,000 tests a day over the next several weeks. Therefore, Quest now expects to perform 150,000 tests per day by next week and to continue to build additional capacity beyond that to 185,000 tests per day by Labor Day."Laboratory innovation is key to optimizing testing capacity for COVID-19," said Quest CEO Steve Rusckowski. "We appreciate the collaboration of the FDA to bring this technique to several of our labs spanning the U.S. With more testing capacity, we expect to improve turnaround times for our customers and patients."Following the FDA approval, six of Quest's US laboratories can now run the new RNA extraction method, including on pooled specimens. The labs are spread across the country to address high testing demand in states where the virus has been surging. The labs are in San Juan Capistrano and Valencia, California; Lewisville, Texas; Lenexa, Kansas; Chantilly, Virginia; and Marlborough, Massachusetts.Quest Diagnostics’ shares have almost doubled since reaching a low in April and are trading 18% higher than at the start of the year.Five-star analyst Donald Hooker at KeyBanc yesterday raised the stock’s rating to Buy from Hold with a $144 price target, saying that that the company is generating estimated earnings of around $1 per share from COVID-19 lab tests.“Patients have re-engaged with the broader healthcare system faster than we had expected, resulting in a sharp recovery in DGX’s core lab testing,” Hooker wrote in a note to investors.The analyst expects COVID-19 molecular and antibody testing to boost Quest’s revenue by over $1.8 billion and earnings by more than 5 cents per share in the second half of 2020. Looking ahead, he sees demand for COVID-19 testing to continue to be at this level through the middle of next year.Overall, Wall Street analysts have a cautiously optimistic outlook on the stock. The Moderate Buy consensus consists of 8 Buys versus 4 Holds. The $139.09 average price target implies another 10% upside potential in the shares in the coming 12 months. (See Quest Diagnostics stock analysis on TipRanks).Related News: Pfizer, BioNTech Rise As Phase 2/3 Covid-19 Vaccine Trial Kicks Off AstraZeneca To Pay Up To $6B For Daiichi Cancer Drug Deal Moderna Could Charge $50-$60 Per Covid-19 Vaccine Course- Report More recent articles from Smarter Analyst: * Cognizant Gains 6% In Pre-Market On 2Q Earnings Beat * Apple Is Said To Face Multi-State US Probe Into Older iPhones * Qualcomm Pops 12% In After-Hours On $1.8B Huawei License Deal * ServiceNow Drops 4% in After-Hours Despite 2Q Earnings Beat
- 07/30/2020
|
Quest Gets FDA Emergency Approval For New Lab Method To Improve Coronavirus Testing Capacity, Speed
- Quest Diagnostics Inc (NYSE: DGX) announced Wednesday it had received an emergency use authorization from the Food and Drug Administration for a new laboratory technique that can help signficantly expand and speed up novel coronavirus (COVID-19) testing.What Happened The Fortune 500 clinical laboratory said in a statement that its new lab technique is related to the extraction of viral RNA from specimens and can also be used for pooled specimens. "We appreciate the collaboration of the FDA to bring this technique to several of our labs spanning the U.S. With more testing capacity, we expect to improve turnaround times for our customers and patients," said Steve Rusckowski, CEO of Quest.The New Jersey-based lab says it can perform 135,000 COVID-19 molecular diagnostic tests a day at present. It claims the new method will add an additional 35,000 tests over the next several weeks. Including specimen pooling, it expects to be able to conduct more than 185,000 tests a day.Quest said the latest EUA will also help speed up the time of getting back the test results in the coming weeks, with an turnaround time of one day for "Priority 1" patients, and two to three days for all other patients.Why It Matters Earlier this month, Quest's SARS-CoV-2 rRT-PCR test became FDA approved for pooled testing, the first such test to receive the agency's clearance.3M Co (NYSE: MMM) is also working in collaboration with the Massachusetts Institute of Technology researchers on a rapid coronavirus test.KeyBanc Capitals Markets analyst Donald Hooker upgraded Quest from Sector Weight to Overweight with a price target of $144, earlier on Wednesday.The analyst expects the demand for COVID-19 testing to remain high through mid-2021.KeyBanc revised earnings estimates for the lab for both 2020 and 2021 from $8.46 to $9 and from $8.83 to $9.10.Price Action Quest shares closed nearly 2.2% higher at $126.20 on Wednesday and added another 1.8% in the after-hours trading.See more from Benzinga(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/30/2020
|
Introducing The Pale Blue Portfolio
- The Pale Blue Portfolio prioritizes corporate responsibility and growth at a reasonable price. It limits the investing universe to companies that receive at least an A grade from MSCI's ESG database.
- 07/29/2020
|
Quest gets FDA OK for speedier COVID-19 testing method
- Quest Diagnostics Inc. said late Wednesday that the U.S. Food and Drug Administration has granted an emergency-use authorization to its new laboratory technique to speed up COVID-19 testing. The new RNA-extraction method will enable the company to expand its daily capacity of COVID-19 tests in the U.S., Quest said. The company currently has the capacity to perform 135,000 COVID-19 tests a day; the new method is expected to add an additional 35,000 tests a day over the next several weeks, Quest said. The company said it continues to build additional capacity to get to 185,000 tests a day by Labor Day. Shares of Quest rose less than 1% in the extended session Wednesday.
- 07/29/2020
|
Quest says FDA cleared new 'lab method' that will cut coronavirus testing delays
- "Covid-19 with the flu season is going to be more problematic than where we're at today," LabCorp CEO Adam Schechter said Tuesday.
- 07/29/2020
|
FDA Authorizes New Quest Diagnostics Lab Method Designed to Increase COVID-19 Molecular Diagnostics Capacity
- Quest Diagnostics (NYSE:DGX) today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for a new laboratory technique that speeds the process of extracting viral RNA from specimens* and will enable the company to expand its daily capacity of COVID-19 molecular diagnostic tests on behalf of patients in the United States.
- 07/29/2020
|
Introducing The Pale Blue Portfolio
- The Pale Blue Portfolio prioritizes corporate responsibility and growth at a reasonable price. It limits the investing universe to companies that receive at least an A grade from MSCI's ESG database.
- 07/29/2020
|
KeyBanc Upgrades Quest Diagnostics, Says Lab Company's Guidance 'Very Cautious'
- Quest Diagnostics Inc (NYSE: DGX) is generating estimated earnings of around $1 per share from COVID-19 lab tests and the Public Health Emergency declaration could continue well into 2021, according to KeyBanc Capital Markets.The Quest Diagnostics Analyst: Donald Hooker upgraded Quest Diagnostics from Sector Weight to Overweight with an unchanged $144 price target. The Quest Diagnostics Thesis: Based on the trends through July, COVID-19 molecular and antibody testing alone could boost Quest's revenue by over $1.8 billion and earnings by more than 5 cents per share in the second half of 2020, Hooker said in the upgrade note.The demand for COVID-19 testing is likely to remain at this elevated level through mid-2021, the analyst said. To reflect this, KeyBanc raised its earnings estimates for 2020 and 2021 from $8.46 to $9 and from $8.83 to $9.10, respectively.These estimates are significantly higher than management's guidance, which appears "very cautious," the analyst said. "Also, patients have re-engaged with the broader healthcare system faster we had expected, resulting in a sharp recovery in DGX's core lab testing," Hooker said.The company was able to maintain its balance sheet strength through the virus outbreak, which is impressive, the analyst said. DGX Price Action: Shares of Quest Diagnostics were trading up 1.6% at $125.43 at last check Wednesday. Related Links:Benzinga's Top Upgrades, Downgrades For July 29, 2020The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOsLatest Ratings for DGX DateFirmActionFromTo Jul 2020KeyBancUpgradesSector WeightOverweight Jul 2020Credit SuisseMaintainsNeutral Jul 2020B of A SecuritiesUpgradesNeutralBuy View More Analyst Ratings for DGX View the Latest Analyst RatingsSee more from Benzinga * Growing Coronavirus Testing Turns Quest Diagnostics Analyst Bullish(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Benzinga's Top Upgrades, Downgrades For July 29, 2020
- Upgrades * For Safe Bulkers Inc (NYSE: SB), DNB Markets upgraded the previous rating of Hold to the current rating Buy. For the first quarter, Safe Bulkers had an EPS of ($0.13), compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $2.25 and a 52-week-low of $0.74. At the end of the last trading period, Safe Bulkers closed at $1.21. * According to SunTrust Robinson Humphrey, the prior rating for Tenable Holdings Inc (NASDAQ: TENB) was changed from Hold to Buy. For the second quarter, Tenable Holdings had an EPS of $0.04, compared to year-ago quarter EPS of ($0.10). The current stock performance of Tenable Holdings shows a 52-week-high of $32.15 and a 52-week-low of $16.28. Moreover, at the end of the last trading period, the closing price was at $30.37. * B of A Securities upgraded the previous rating for U.S. Xpress Enterprises Inc (NYSE: USX) from Neutral to Buy. In the second quarter, U.S. Xpress Enterprises showed an EPS of $0.18, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $7.63 and a 52-week-low of $2.65. At the end of the last trading period, U.S. Xpress Enterprises closed at $6.78. * For Zynex Inc (NASDAQ: ZYXI), B. Riley FBR upgraded the previous rating of Neutral to the current rating Buy. In the second quarter, Zynex showed an EPS of $0.09, compared to $0.06 from the year-ago quarter. At the moment, the stock has a 52-week-high of $29.73 and a 52-week-low of $7.51. Zynex closed at $18.51 at the end of the last trading period. * For Arlo Technologies Inc (NYSE: ARLO), Raymond James upgraded the previous rating of Market Perform to the current rating Outperform. Arlo Technologies earned ($0.34) in the first quarter, compared to ($0.47) in the year-ago quarter. The stock has a 52-week-high of $5.13 and a 52-week-low of $1.20. At the end of the last trading period, Arlo Technologies closed at $3.29. * According to Rosenblatt, the prior rating for Rockwell Automation Inc (NYSE: ROK) was changed from Sell to Neutral. In the third quarter, Rockwell Automation showed an EPS of $1.27, compared to $2.40 from the year-ago quarter. The stock has a 52-week-high of $230.93 and a 52-week-low of $115.38. At the end of the last trading period, Rockwell Automation closed at $222.25. * For Quest Diagnostics Inc (NYSE: DGX), KeyBanc upgraded the previous rating of Sector Weight to the current rating Overweight. For the second quarter, Quest Diagnostics had an EPS of $1.42, compared to year-ago quarter EPS of $1.73. At the moment, the stock has a 52-week-high of $131.81 and a 52-week-low of $73.02. Quest Diagnostics closed at $123.50 at the end of the last trading period. Downgrades * For Align Technology Inc (NASDAQ: ALGN), Berenberg downgraded the previous rating of Buy to the current rating Hold. Align Tech earned ($0.35) in the second quarter, compared to $1.83 in the year-ago quarter. At the moment, the stock has a 52-week-high of $326.36 and a 52-week-low of $127.88. Align Tech closed at $299.11 at the end of the last trading period. * For Armstrong World Industries Inc (NYSE: AWI), Evercore ISI Group downgraded the previous rating of In-Line to the current rating Underperform. Armstrong World Indus earned $0.75 in the second quarter, compared to $1.27 in the year-ago quarter. The current stock performance of Armstrong World Indus shows a 52-week-high of $111.46 and a 52-week-low of $62.03. Moreover, at the end of the last trading period, the closing price was at $72.00. * For National CineMedia Inc (NASDAQ: NCMI), Wedbush downgraded the previous rating of Outperform to the current rating Neutral. National CineMedia earned ($0.05) in the first quarter, compared to ($0.01) in the year-ago quarter. At the moment, the stock has a 52-week-high of $9.85 and a 52-week-low of $1.62. National CineMedia closed at $2.94 at the end of the last trading period. * Raymond James downgraded the previous rating for Sonos Inc (NASDAQ: SONO) from Strong Buy to Market Perform. In the second quarter, Sonos showed an EPS of ($0.48), compared to ($0.22) from the year-ago quarter. The current stock performance of Sonos shows a 52-week-high of $17.83 and a 52-week-low of $6.58. Moreover, at the end of the last trading period, the closing price was at $16.45. * According to RBC Capital, the prior rating for T-Mobile US Inc (NASDAQ: TMUS) was changed from Outperform to Sector Perform. In the first quarter, T-Mobile US showed an EPS of $1.10, compared to $1.06 from the year-ago quarter. The stock has a 52-week-high of $111.58 and a 52-week-low of $63.50. At the end of the last trading period, T-Mobile US closed at $104.52. * According to Benchmark, the prior rating for Seagate Technology PLC (NASDAQ: STX) was changed from Buy to Hold. For the fourth quarter, Seagate Technology had an EPS of $1.20, compared to year-ago quarter EPS of $0.86. At the moment, the stock has a 52-week-high of $64.17 and a 52-week-low of $39.02. Seagate Technology closed at $48.57 at the end of the last trading period. * Bernstein downgraded the previous rating for ASML Holding NV (NASDAQ: ASML) from Outperform to Market Perform. ASML Holding earned $1.97 in the second quarter, compared to $1.27 in the year-ago quarter. The stock has a 52-week-high of $402.87 and a 52-week-low of $191.25. At the end of the last trading period, ASML Holding closed at $376.36. Initiations * Oppenheimer initiated coverage on Bill.com Holdings Inc (NYSE: BILL) with an Outperform rating. The price target for Bill.com Holdings is set to $103.00. In the first quarter, Bill.com Holdings earned ($0.04). The current stock performance of Bill.com Holdings shows a 52-week-high of $97.84 and a 52-week-low of $23.61. Moreover, at the end of the last trading period, the closing price was at $85.05. * With a current rating of Outperform, Credit Suisse initiated coverage on Flexion Therapeutics Inc (NASDAQ: FLXN). The price target seems to have been set at $19.00 for Flexion Therapeutics. Flexion Therapeutics earned ($0.95) in the first quarter, compared to ($1.09) in the year-ago quarter. The current stock performance of Flexion Therapeutics shows a 52-week-high of $22.98 and a 52-week-low of $5.01. Moreover, at the end of the last trading period, the closing price was at $12.49. * Evercore ISI Group initiated coverage on Principia Biopharma Inc (NASDAQ: PRNB) with an Outperform rating. The price target for Principia Biopharma is set to $130.00. In the first quarter, Principia Biopharma showed an EPS of ($0.99), compared to ($0.57) from the year-ago quarter. At the moment, the stock has a 52-week-high of $94.91 and a 52-week-low of $25.35. Principia Biopharma closed at $84.39 at the end of the last trading period. * With a current rating of Buy, Deutsche Bank initiated coverage on T-Mobile US Inc (NASDAQ: TMUS). The price target seems to have been set at $140.00 for T-Mobile US. For the first quarter, T-Mobile US had an EPS of $1.10, compared to year-ago quarter EPS of $1.06. The current stock performance of T-Mobile US shows a 52-week-high of $111.58 and a 52-week-low of $63.50. Moreover, at the end of the last trading period, the closing price was at $104.52. * Guggenheim initiated coverage on Protara Therapeutics Inc (NASDAQ: TARA) with a Buy rating. The price target for Protara Therapeutics is set to $50.00. Protara Therapeutics earned ($1.81) in the first quarter, compared to ($0.58) in the year-ago quarter. At the moment, the stock has a 52-week-high of $67.08 and a 52-week-low of $19.22. Protara Therapeutics closed at $27.45 at the end of the last trading period. * HC Wainwright & Co. initiated coverage on argenx SE (NASDAQ: ARGX) with a Neutral rating. The price target for argenx is set to $272.00. In the first quarter, argenx showed an EPS of ($2.06), compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $272.74 and a 52-week-low of $103.75. argenx closed at $253.23 at the end of the last trading period.See more from Benzinga * How Does Boeing's Debt Look Like? * General Dynamics's Debt Overview * Boston Scientific's Debt Overview(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Here are Wednesday's biggest analyst calls of the day: Tesla, Apple, L Brands, Netflix & more
- Here are the biggest calls on Wall Street on Wednesday
- 07/29/2020
|
KeyBanc Upgrades Quest Diagnostics, Says Lab Company's Guidance 'Very Cautious'
- Quest Diagnostics Inc (NYSE: DGX) is generating estimated earnings of around $1 per share from COVID-19 lab tests and the Public Health Emergency declaration could continue well...
- 07/29/2020
|
Bill Gates says delays in coronavirus test results make them a 'complete waste,' 'insane'
- "You should not reimburse somebody for getting a test that it takes more than 48 hours to get the result back," Bill Gates told CNBC.
- 07/28/2020
|
Stocks making the biggest moves in the premarket: McDonald's, 3M, Pfizer, Harley-Davidson & more
- The stocks making the biggest moves in premarket trading include McDonald's, 3M, Pfizer, Harley-Davidson, and more.
- 07/28/2020
|
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 07/27/2020
|
Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie
- Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie
- 07/27/2020
|
Results: Quest Diagnostics Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
- As you might know, Quest Diagnostics Incorporated (NYSE:DGX) recently reported its second-quarter numbers. The result...
- 07/26/2020
|
Quest Diagnostics Incorporated's (NYSE:DGX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
- Most readers would already be aware that Quest Diagnostics' (NYSE:DGX) stock increased significantly by 22% over the...
- 07/24/2020
|
Quest Diagnostics Inc (DGX) Q2 2020 Earnings Call Transcript | AlphaStreet
- Quest Diagnostics Inc (NYSE: DGX) Q2 2020 earnings conference call dated July 23, 2020
- 07/24/2020
|
Coronavirus update: Global COVID-19 cases top 15 million, U.S. cases pass 4 million, and California has more cases than New York
- The number of confirmed cases of the coronavirus illness COVID-19 worldwide climbed above 15 million on Thursday and the U.S. case tally passed 4 million, as...
- 07/24/2020
|
Quest medical lab sees COVID-19 test speed at 'acceptable' level by Sept
- It aims to increase COVID-19 diagnostic testing to 150,000 per day by next month and ultimately to exceed that level. A shortfall of adequate diagnostic testing has hampered the U.S. response to the pandemic, which has so far infected more than 4 million Americans. "We'll be able to get the turnaround times that are in the acceptable levels that we've had in the past."
- 07/24/2020
|
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 23)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Acceleron Pharma Inc (NASDAQ: XLRN)
Aerpio...
- 07/24/2020
|
Quest Diagnostics Inc (DGX) Q2 2020 Earnings Call Transcript
- DGX earnings call for the period ending June 30, 2020.
- 07/23/2020
|
Dow logs 350-point loss as shares of Apple and Microsoft exact heavy toll on the blue-chip index, broader stock market
- U.S. stocks end Thursday sharply lower, with technology-related giants Apple and Microsoft at the vanguard of a selloff in large-capitalization stocks.
- 07/23/2020
|
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2020 Results - Earnings Call Transcript
- Quest Diagnostics Incorporated (NYSE:DGX) Q2 2020 Results Conference Call July 23, 2020 08:30 ET Company Participants Shawn Bevec - Vice President of Investor Relations Steve Rusckowski - Chairman, Chief Executive Officer & President Mark Guinan - Chief Financial Officer Conference Call Participants Ann Hynes - Mizuho Securities Stephen Baxter - Wolfe Research Jack Meehan - Nephron Research Ricky Goldwasser - Morgan Stanley Ralph Giacobbe - Citi Pito Chickering - Deutsche Bank Kevin Caliendo - UBS Lisa Gill - JPMorgan Matt Larew - William Blair Brian Tanquilut - Jefferies Eric Coldwell - Robert W.
- 07/23/2020
|
Quest says small labs ripe for acquisition as coronavirus pandemic sets stage for industry consolidation
- "If anything, the pandemic could be an essential catalyst to help drive industry consolidation," Quest CEO Steve Rusckowski said.
- 07/23/2020
|
How Quest Diagnostics Beat Earnings Estimates in the Second Quarter
- The diagnostics information services provider's shares were up more than 20% as of the market close on Wednesday. The company reported net income in the second quarter of $185 million, or $1.36 per diluted share, based on generally accepted accounting principles (GAAP). This reflected a significant drop from Quest's GAAP earnings in the prior-year period of $226 million, or $1.66 per diluted share.
- 07/23/2020
|
Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines
- Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.
- 07/23/2020
|
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
ABIOMED, Inc. (NASDAQ: ABMD)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
Bio-Rad Laboratories,...
- 07/23/2020
|
COVID-19 Impact & Recovery Analysis - Specimen Validity Testing Market (2020-2024) | Rising Consumption of Alcohol and Illicit Drugs to Boost Growth | Technavio
- The Global Specimen Validity Testing Market will grow by USD 393.04 mn during 2020-2024
- 07/22/2020
|
LabCorp CEO says coronavirus in U.S. is spreading faster than it can add testing capacity
- "We need all states to ensure we're doing everything we can to better control the virus. If we can do that, then we'll be able to have the tests that we need," LabCorp CEO Adam Schechter told CNBC.
- 07/21/2020
|
OPKO Health Is Likely To Double From Here
- Over 700,000 COVID-19 tests are being performed daily across the US. OPKO Health's wholly owned subsidiary, BioReference Labs is the nation's third-largest diagnostics laboratory.
- 07/20/2020
|
Quest Wins First FDA Approval To Conduct ‘Pooled’ COVID Testing
- In an effort to increase testing capacity, Quest Diagnostics will now be allowed to “pool” up to four samples together. If the group comes back positive, samples will be tested individu…
- 07/20/2020
|
Monday, July 20, 2020
- Visit the post for more.
- 07/20/2020
|
Defiant Fauci tells InStyle magazine: ‘With all due modesty, I think I’m pretty effective’
- Posing poolside in sunglasses and stars-and-stripes socks, Anthony Fauci says: ‘I don’t regret anything I said.’
- 07/20/2020
|
Quest Scores US Nod For Covid-19 Test Pooling; Speeding Up Response Times
- Quest Diagnostics (DGX) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use specimen pooling with its
- 07/20/2020
|
Redpoint Investment Management Pty Ltd Sells 380 Shares of Quest Diagnostics Inc (NYSE:DGX)
- Redpoint Investment Management Pty Ltd cut its holdings in shares of Quest Diagnostics Inc (NYSE:DGX) by 2.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,817 shares of the medical research company’s stock after selling 380 shares during the quarter. Redpoint […]
- 07/20/2020
|
FDA approves faster Quest COVID-19 test for ‘pooled’ sample use
- The Food and Drug Administration has given emergency approval to a new approach to coronavirus testing that combines test samples in batches instead of...
- 07/19/2020
|
FDA approves Quest COVID-19 test for 'pooled' sample use
- The Food and Drug Administration has issued an emergency approval a new approach to coronavirus testing in which several people's samples are tested together in batches instead of individually, speeding up the process
- 07/19/2020
|
FDA approves Quest COVID-19 test for 'pooled' sample use
- The Food and Drug Administration has issued an emergency approval a new approach to coronavirus testing in which several people's samples are tested together in batches instead of individually, speeding up the process
- 07/19/2020
|
Parallel Advisors LLC Increases Stock Position in Quest Diagnostics Inc (NYSE:DGX)
- Parallel Advisors LLC boosted its stake in shares of Quest Diagnostics Inc (NYSE:DGX) by 16.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,528 shares of the medical research company’s stock after buying an additional 634 shares during […]
- 07/19/2020
|
Quest Diagnostics : Media Statement about COVID-19 Testing | MarketScreener
|
Quest Diagnostics : FDA Authorizes Quest Diagnostics COVID-19 Diagnostic Testing for Specimen Pooling for Emergency Use | MarketScreener
|
Dividend Challenger Highlights: Week Of July 19
- A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends.
- 07/18/2020
|
Harbor Investment Advisory LLC Boosts Holdings in Quest Diagnostics Inc (NYSE:DGX)
- Harbor Investment Advisory LLC grew its position in Quest Diagnostics Inc (NYSE:DGX) by 251.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,424 shares of the medical research company’s stock after buying an additional 1,735 shares during the period. […]
- 07/18/2020
|
Exchange Traded Concepts LLC Increases Stake in Quest Diagnostics Inc (NYSE:DGX)
- Exchange Traded Concepts LLC boosted its position in Quest Diagnostics Inc (NYSE:DGX) by 6,231.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,849 shares of the medical research company’s stock after purchasing an additional 2,804 shares during the period. […]
- 07/18/2020
|
'The virus doesn't care about excuses': US faces terrifying autumn as Covid-19 surges
- The breathing space afforded by lockdowns in the spring has been squandered, with new cases running at five times the rate of the whole of Europe. Things will only get worse, experts warn
- 07/18/2020
|
Earnings and fiscal debate could be catalysts for stocks in the week ahead
- Investors are braced for a barrage of earnings news, and the debate in Congress around fiscal stimulus may also be an important catalyst.
- 07/17/2020
|
Coronavirus update: US sets new daily record as domestic political divisions harden over masks
- The United States shattered its daily coronavirus case record with more than 73,000 new cases, adding to the exponential growth of the outbreak in the top global hotspot, as political divisions widen over the need for a national face mask policy.
- 07/17/2020
|
Testing Volume to Aid Quest Diagnostics' (DGX) Q2 Earnings?
- Looking at this demand for testing, Quest Diagnostics (DGX) has significantly picked up capacity to perform molecular diagnostic tests a day.
- 07/17/2020
|
Quest Diagnostics (DGX) Soars to 52-Week High, Time to Cash Out?
- Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 07/17/2020
|
MERIAN GLOBAL INVESTORS UK Ltd Invests $418,000 in Quest Diagnostics Inc (NYSE:DGX)
- MERIAN GLOBAL INVESTORS UK Ltd acquired a new position in Quest Diagnostics Inc (NYSE:DGX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,673 shares of the medical research company’s stock, valued at approximately $418,000. Several other large investors have also recently made changes […]
- 07/17/2020
|
Quest Diagnostics Inc (NYSE:DGX) Shares Acquired by CENTRAL TRUST Co
- CENTRAL TRUST Co boosted its holdings in Quest Diagnostics Inc (NYSE:DGX) by 5.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,604 shares of the medical research company’s stock after acquiring an additional 135 shares during the period. CENTRAL TRUST Co’s holdings in Quest Diagnostics […]
- 07/17/2020
|
The perils of waiting 10 days or more to get a coronavirus test result: ‘It’s only marginally better than not doing the testing’
- When people first started showing signs of coronavirus in the U.S. in March they were told they needed special permission to get tested. If they didn’t fit...
- 07/17/2020
|
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 16)
AC Immune SA (NASDAQ: ACIU...
- 07/17/2020
|
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/16/2020
|
Here's Why Quest Diagnostics (DGX) is a Great Momentum Stock to Buy
- Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/16/2020
|
Quest Diagnostics (NYSE:DGX) Rating Increased to Buy at Bank of America
- Quest Diagnostics (NYSE:DGX) was upgraded by Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage currently has a $142.00 price objective on the medical research company’s stock. Bank of America‘s target price indicates a potential upside of 15.72% […]
- 07/16/2020
|
Sweden’s Premier Defends Policy; ICU Deaths Drop: Virus Update
- (Bloomberg) -- Swedish Prime Minister Stefan Lofven defended his country’s controversial strategy to fight the pandemic. Tokyo joined Australia’s second-biggest state in posting record coronavirus cases as second waves spread in several hotspots.Fewer Covid-19 patients are dying in intensive-care units. Overall mortality of patients treated in ICUs had fallen to just under 42% at the end of May from almost 60% in March, according to an analysis of studies involving more than 10,000 patients in Asia, Europe and North America.Quarterly earnings out Thursday are showing the hit to companies on the wrong side of shifts in how people spend their money. Luxury-goods maker Richemont saw almost half of its sales wiped out while brewer Heineken NV reported a plunge in profit as lockdowns decimated sales to bars and restaurants.Key Developments:Global Tracker: Cases top 13.5 million; deaths surpass 584,000The number of cases of unknown origin will determine lockdown responsesGreenwich mansions are all the rage in the pandemic eraTexas readies morgue trucks in preparation for virus surgeChina will allow cinemas to open in low-risk areas starting July 20Subscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus.Pressure on AstraZeneca (3:59 p.m. HK)Pressure is growing on AstraZeneca Plc to deliver positive results from early tests evaluating the coronavirus vaccine it’s developing with University of Oxford researchers as investors await data expected on Monday.The U.K. pharma company is staying quiet after British media reports said results of phase 1 tests to be published in The Lancet medical journal were promising, driving the shares up on Wednesday.Working Hours Slump Signals Trouble for U.K. Labor (3:51 p.m. HK)The number of hours worked in the U.K. economy fell the most on the record in the coronavirus lockdown, underlining the risk facing the labor market as government income support is phased out.Hours plunged by 175 million in the three months through May, or almost 17%, to their lowest level since 1997, the Office for National Statistics said. Employment fell, vacancies dropped sharply and wage growth slowed to a virtual standstill.Bank Indonesia Cuts Rates for Second Month (3:28 p.m. HK)Bank Indonesia lowered its key interest rate for a second straight month, seeking to help the economy recover from the devastating impact of the coronavirus pandemic.The central bank cut its seven-day reverse repurchase rate by 25 basis points to 4%, the lowest since the current rate system was adopted in 2016, as predicted by 18 of 30 economists surveyed by Bloomberg. One expected a 50 basis-point cut, while the other 11 expected the bank to hold rates steady.Melbourne’s Monash University to Cut Jobs (3:08 p.m. HK)Melbourne’s Monash University will cut 277 jobs by the end of the year due to pandemic-related losses of more than A$300 million ($210 million), the Australian newspaper reported Thursday, citing a spokesperson.The target consists of 105 academic positions while the remainder will be administrative roles.De Beers Sold Almost No Diamonds (2:41 p.m. HK)Anglo American Plc’s De Beers diamond business sold almost no gems in the second quarter, highlighting how badly the sector has been hit by coronavirus-enforced lockdowns.The world’s biggest producer sold $56 million of rough diamonds, down about 96% from a year earlier when sales totaled $1.3 billion. With jewelry stores closed, cutters and polishers stuck at home and global travel at a standstill, the entire diamond industry essentially came to a halt in the period.Beer, Watches Feel the Pain of Lockdowns (2:51 p.m. HK)The change in how people and companies spend their money through the pandemic reads like a tale of two economies. Quarterly earnings out Thursday are showing the hit to those on the wrong side of these structural shifts.Richemont –- heavily reliant on a decimated tourism industry –- saw almost half of its sales evaporate in the three months through June. Heineken NV reported a plunge in profit as lockdowns wiped out sales to bars and restaurants and led to a big impairment charge.Companies lucky enough to be in the winning segments of the economy, such as online fashion retailer Zalando SE and laboratory-equipment maker Sartorius AG, are riding high. Those reliant on broader economic confidence are struggling to see through the gloom, with recruitment firm Hays Plc saying the outlook is “highly uncertain.”Sweden Defends Controversial Virus Strategy (2:40 p.m. HK)Swedish Prime Minister Stefan Lofven said he has no doubt his country’s highly controversial strategy for fighting Covid-19 remains appropriate, even as the country’s mortality rate tops the U.S.Lofven, who has seen his popularity flag as Sweden’s decision not to impose a proper lockdown was followed by a spike in deaths, said he still thinks “the strategy is right, I’m completely convinced of that,” according to an interview with Aftonbladet.U.K. Labor Market Holds Up (2:17 p.m. HK)U.K. jobless claims fell in June and the economy lost fewer jobs than expected in the three months through May as government income support kept millions of people in work.The number of people seeking unemployment benefits fell 28,100 to 2.63 million, and employment fell by less than half the expected drop, the Office for National Statistics said. The headline jobless rate stayed at 3.9%.Indonesia Plans to Punish Virus Rule Breakers (1:40 p.m. HK)Indonesia plans to fine violators of social distancing rules under a new law as President Joko Widodo steps up efforts to contain the biggest outbreak of coronavirus in Southeast Asia.Provincial chiefs will determine the types of punishment for offenders, taking into account local traditions, Widodo told a meeting of governors in Jakarta. Earlier this week, the president told a cabinet meeting that people not wearing masks in public and those failing to maintain physical distance may be ordered to pay a fine or do social service.Tokyo, Victoria Daily Records (12:25 p.m. HK)Tokyo is set to report a daily record of over 280 coronavirus cases Thursday, heightening concerns that the latest infection is spreading in the broader community and set to spill beyond the capital. The number comes after the city conducted more than 4,000 tests, also a record.While the initial flare-up in Tokyo came from nightclubs, with increased daily numbers coming from more aggressive testing of bar workers, authorities have expressed concern that more cases are now coming from more everyday locales such as restaurants, bars and workplaces. Only 13 of 165 cases reported in Tokyo on Wednesday were traced to the clubs.Meanwhile Victoria, Australia’s second most populous state, recorded 317 new cases in the past 24 hours, its biggest spike in coronavirus cases. The increase comes a week after it was placed into partial lockdown and it’s the largest single-day rise for any of Australia’s states and territories, according to data compiled by Bloomberg.ICU Death Rate Is Declining (8:45 a.m. HK)Overall mortality of Covid-19 patients treated in intensive-care units fell to just under 42% at the end of May from almost 60% in March, according to the first systematic analysis of two dozen studies involving more than 10,000 patients in Asia, Europe and North America.The fast spread of SARS-CoV-2, high caseload and proportion of patients requiring breathing support placed “unprecedented demand” on ICU services, researchers wrote in a study published Wednesday in the journal Anaesthesia. Countries in the later phases of the pandemic may now be coping better, they said.Air Canada Urges Trudeau to Relax Travel Rules (7:25 a.m. HK)Air Canada tried to persuade the government of Justin Trudeau to ease restrictions on travel, pointing to policy shifts in other nations where the pandemic has shown signs of improvement.In a letter to Transport Minister Marc Garneau and other cabinet members, the airline’s chief medical officer suggested loosening quarantine requirements through “a science-based approach” to strike a balance between economic and public health concerns. In following some countries in Europe and Asia, Canada would enable a “measured restart of aviation,” he said.Record Day of Deaths in Texas (6:47 a.m. HK)Texas recorded its grimmest day yet with a record 110 Covid-19 deaths and almost 11,000 new cases, according to state health department data. The increase brought the Lone Star state’s death toll since the start of the pandemic to 3,432.Hospitalizations ticked down by less than 1% statewide for just the second daily decline since late June, state figures showed. Reporting lags continued to bedevil efforts to assess the outbreak’s trajectory. Houston Mayor Sylvester Turner said in tweets that some fatalities reported on Wednesday occurred as long ago as early May.World Leaders Want Vaccine Fairness (6:10 a.m. HK)Eight world leaders including President Sahle-Work Zewde of Ethiopia and Sweden’s Lofven issued a call for “global solidarity” for fairness in distributing any Covid-19 vaccine that may be developed.Supplies of a vaccine should be shared fairly among all nations and people of all income levels, the leaders said in an opinion piece published in the Washington Post. An organized global flow of vaccines will require “mutual trust, transparency and accountability” among nations, they said.Also signing the statement were prime ministers Justin Trudeau of Canada; New Zealand’s Jacinda Ardern; Pedro Sanchez of Spain and Tunisia’s Elyes Fakhfakh, who later resigned; as well as presidents Moon Jae-in of South Korea and Cyril Ramaphosa of South Africa.California Cases, Deaths Rise (1:45 p.m. SF)New coronavirus cases and deaths in California surged to near-record highs, as the pandemic rebounds in the biggest U.S. state.
- 07/16/2020
|
Credit Suisse Group Increases Quest Diagnostics (NYSE:DGX) Price Target to $128.00
- Quest Diagnostics (NYSE:DGX) had its price target boosted by investment analysts at Credit Suisse Group from $126.00 to $128.00 in a research note issued to investors on Tuesday, BenzingaRatingsTable reports. The firm currently has a “neutral” rating on the medical research company’s stock. Credit Suisse Group’s price target points to a potential upside of 4.31% […]
- 07/16/2020
|
Increased wait times for COVID-19 test results coincide with higher rates of infection among younger people
- The challenge of quarantining at home while awaiting a test result only grows the longer the results take to come back.
- 07/15/2020
|
Slow Covid-19 Data Call For a Smarter Approach
- (Bloomberg Opinion) -- Covid-19 has been devilishly difficult to monitor, and therefore to control, in part because of the degree to which data lag reality. This happens because each link in the chain of illness is long: Exposure to the coronavirus takes time to manifest as illness, which in turn takes time to register positive on a Covid test, which result then takes time to be reported — and so on down a long line. Delays are a feature of any infectious disease outbreak, but they are especially lengthy for this virus.Also, because the novel coronavirus doesn’t immediately or consistently produce symptoms, the germ can spread quietly. In the U.S., public health strategies that vary from state to state, inconsistent support from the federal government, and a fragmented health system with antiquated record-keeping systems only make it harder to discern a clear picture of the epidemic. The unfortunate result is that many state leaders underestimate trouble ahead. California, with its growing case count, has just imposed significant new restrictions on indoor activity — a sign that at least one state sees the writing on the wall. Others remain too reluctant to act. Covid has been hard to manage from the beginning in the U.S., thanks to the shortage of testing. But since reopening began, the problem has grown worse in some respects. Governors have had to find their way without firm national guidance. The only clear message from Washington has been encouragement to reopen as fast as possible.Guidelines issued by the White House’s coronavirus task force were sensible, but widely ignored. They advised states to watch the data and, before taking steps to emerge from lockdown, make sure they saw 14-day declines in the number of cases and in the rate of positive tests. That two-week benchmark wasn’t set in stone, but was recommended as a precaution to ensure that each successive phase of reopening could go forward without a worrisome outbreak or surge. Two weeks was enough time to account for lags in the data.However, several states didn’t bother to wait even long enough to meet the first threshold. Some sped through subsequent data gates without conducting robust contact tracing or logging declining infection rates. Then, even as case counts and positive-test rates began to rise, state leaders said it was OK not to worry, because hospitalizations remained low and deaths, lower still. The first of those data points has caught up, and daily deaths, the slowest of metrics, are catching up in several states enough to cause a significant boost in the national data.Renewed testing delays make the near future look pretty grim. Testing giant Quest Diagnostics Inc. now reports a seven-day average turnaround time for anything but high-priority tests. That suggests outbreaks will again get ahead of any rise in state case numbers. More than a dozen states are already seeing positive-test rates above 10%. To make matters worse, they’re reporting ongoing difficulties procuring tests, which will make it harder to identify, inform and isolate the infected. California’s new restrictions on indoor activity acknowledge the Covid data lag. The state’s current infection numbers — which are concerning, if not as high as those in other states — reflect the behavior of Californians as much as two weeks ago. And the new mitigation steps will take time to bring the numbers down. Other states should note that the larger an outbreak is, the more untracked infections there will be, and thus the more the data will lag.And the looser the restrictions on movement and behavior, the longer it will take to turn things around. Earlier action brings faster results. Although California’s new rules do not amount to a full spring-style lockdown, they will still hamper the state’s economy. To allow uncontained spread would be just as harmful, however, and would make it impossible to safely open schools. The rollback will slow case growth, give testing capacity time to catch up, and enable the state to schedule a more patient and sustainable re-reopening. More states may need to follow California’s example, especially as flu season arrives. While this will disappoint anyone hoping for a linear recovery, it might help all states come to better understand how the Covid data chain works, and why it’s essential to monitor it carefully. The alternative is to continue muddling through a pandemic with a strategy based not on data but only on hope.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/15/2020
|
NBA says it's adding coronavirus testing resources in Florida, not taking them away from the community
- As the NBA restarts in the Orlando bubble, Covid-19 testing is frequent and results come quickly. The league has been criticized for taking away resources and supplies, but it says it's increasing resources.
- 07/15/2020
|
U.S. reports record 67,400 single-day spike of new coronavirus cases
- "The time is now," Dr. Robert Redfield, Director of the CDC, said Tuesday. "I think if we could get everybody to wear a mask right now I think in four, six, eight weeks we could bring this epidemic under control."
- 07/15/2020
|
Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Third Consecutive Year
- SECAUCUS, N.J., July 15, 2020 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has been named to the 2020 Disability Equality Index (DEI) "Best Places to Work for Disability Inclusion" by Disability:IN and the American Association of People with Disabilities (AAPD).
- 07/15/2020
|
Campus Health Project to Speak at LEAD1 Association’s COVID-19 Testing Webinar
- Campus Health Project to Speak at LEAD1 Association’s COVID-19 Testing Webinar
- 07/15/2020
|
Trump says U.S. would have half the number of coronavirus cases if it did half the testing
- Trump said that while coronavirus testing "is a good thing," it has also served as "fodder for the fake news to report cases."
- 07/14/2020
|
U.S. seven-day average of new coronavirus cases surpass 60,000 for the first time
- The U.S. surpassed more than 60,000 new coronavirus cases, based on a seven-day moving average, for the first time on Monday, according to a CNBC analysis of data compiled by Johns Hopkins University.
- 07/14/2020
|
Were Hedge Funds Right About Piling Into Quest Diagnostics Incorporated (DGX)?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/14/2020
|
IPO Update: Renalytix AI Proposes IPO Terms
|
DGX vs. USPH: Which Stock Should Value Investors Buy Now?
- DGX vs. USPH: Which Stock Is the Better Value Option?
- 07/14/2020
|
Growing Coronavirus Testing Turns Quest Diagnostics Analyst Bullish
- Quest Diagnostics Inc (NYSE: DGX) preannounced its second-quarter revenue at around $1.83 billion on Monday, beating Street estimates by about 18%. Preliminary also came in ahead, in the range of $1.39-$1.42 per share versus the Street's 18-cent estimate. The company's second-quarter earnings were driven by a faster recovery in core testing volumes and growing COVID-19 testing services, according to BofA Securities.The Quest Diagnostics Analyst: Derik de Bruin upgraded Quest Diagnostics from Neutral to Buy and raised the price target from $124 to $142.The Quest Diagnostics Thesis: Coronavirus testing tailwinds are likely to last longer than was previously anticipated, de Bruin said in a Tuesday upgrade note. (See his track record here.)The analyst named the reasons for the prolonged tailwinds as: * Deteriorating coronavirus situation in the U.S. * Uncertainties around when a vaccine can be approved * Doubts around herd immunity developing * Potential for repeated waves of the virus"We are still skeptical on serology testing and continue to assume a lower utilization rate, but we expect molecular testing (MDx) demand and utilization should continue at a high level," de Bruin said. View more earnings on DGXThe analyst raised the revenue estimates for fiscal 2021 and 2022 from $7.542 billion to $8.134 billion and from $8.110 billion to $8.825 billion, respectively. BofA also raised the earnings estimates for the years from $4.20 per share to $6.30 per share and from $7.60 per share to $8.40 per share, respectively.DGX Price Action: Shares of Quest Diagnostics were trading 0.77% higher to $120.06 at last check.Related Links:Benzinga's Top Upgrades, Downgrades For July 14, 2020Moderna, Other Vaccine Developers Lead The Way In New GERM ETFLatest Ratings for DGX DateFirmActionFromTo Jul 2020Credit SuisseMaintainsNeutral Jul 2020B of A SecuritiesUpgradesNeutralBuy Jun 2020Wells FargoUpgradesUnderweightEqual-Weight View More Analyst Ratings for DGX View the Latest Analyst RatingsSee more from Benzinga * Piper Sandler More Than Doubles Tesla Price Target, Sees 'Most Consequential Company' In Mobility * BofA Cuts Carnival Target, With Slow Cruise Line Recovery Ahead * Morgan Stanley Raises Apple Price Target On iPhone Trade-In Opportunity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/14/2020
|
How Does Quest Diagnostics' Debt Look Like?
- Over the past three months, shares of Quest Diagnostics Inc. (NYSE: DGX) rose by 25.93%. Before we understand the importance of debt, let's look at how much debt Quest Diagnostics has.Quest Diagnostics's Debt Based on Quest Diagnostics's balance sheet as of May 4, 2020, long-term debt is at $4.03 billion and current debt is at $3.00 million, amounting to $4.04 billion in total debt. Adjusted for $342.00 million in cash-equivalents, the company's net debt is at $3.69 billion.To understand the degree of financial leverage a company has, investors look at the debt ratio. Considering Quest Diagnostics's $12.05 billion in total assets, the debt-ratio is at 0.33. As a rule of thumb, a debt-ratio more than 1 indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. For example, a debt ratio of 35% might be higher for one industry, whereas normal for another.Importance of Debt Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.However, due to interest-payment obligations, cash-flow of a company can be impacted. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.See more from Benzinga * Benzinga's Top Upgrades, Downgrades For July 14, 2020 * Benzinga's Top Upgrades, Downgrades For June 9, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/14/2020
|
5 things to know before the stock market opens Tuesday
- U.S. stock futures traded higher as investors tried to regain their footing after a massive late-day turnaround in the previous session.
- 07/14/2020
|
Whittier Trust Co. Decreases Stock Holdings in Quest Diagnostics Inc (NYSE:DGX)
- Whittier Trust Co. lessened its holdings in Quest Diagnostics Inc (NYSE:DGX) by 3.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,949 shares of the medical research company’s stock after selling 100 shares during the period. Whittier Trust Co.’s holdings in […]
- 07/14/2020
|
Quest Diagnostics Inc (NYSE:DGX) Position Cut by Alpha Windward LLC
- Alpha Windward LLC trimmed its stake in Quest Diagnostics Inc (NYSE:DGX) by 28.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,181 shares of the medical research company’s stock after selling 1,258 shares during the quarter. Alpha Windward LLC’s holdings in Quest Diagnostics were worth $363,000 as […]
- 07/14/2020
|
575 Shares in Quest Diagnostics Inc (NYSE:DGX) Purchased by Patriot Financial Group Insurance Agency LLC
- Patriot Financial Group Insurance Agency LLC acquired a new position in shares of Quest Diagnostics Inc (NYSE:DGX) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 575 shares of the medical research company’s stock, valued at approximately $66,000. A number of other hedge funds also recently made changes to their positions in the […]
- 07/14/2020
|
Growing Coronavirus Testing Turns Quest Diagnostics Analyst Bullish
- Quest Diagnostics Inc (NYSE: DGX) preannounced its second-quarter revenue at around $1.83 billion on Monday, beating Street estimates by about 18%. Preliminary also...
- 07/14/2020
|
U.S. coronavirus surge leads to testing delays across the nation, Quest Diagnostics says
- "Yet, we want patients and healthcare providers to know that we will not be in a position to reduce our turnaround times as long as cases of COVID-19 continue to increase dramatically across much of the United States," the company said.
- 07/13/2020
|
Quest Diagnostics : Media Statement about COVID-19 Testing | MarketScreener
|
How to Be Ready for the Next Pandemic
- Step 1 is to learn from our mistakes fighting Covid-19, say leading biodefense experts.
- 07/13/2020
|
Stocks making the biggest moves midday: Pfizer, Apple, Moderna, Tesla, PepsiCo & more
- PepsiCo rose on better-than-expected results for the previous quarter. Tesla shares hit an all-time high.
- 07/13/2020
|
Coronavirus update: Global case tally edges toward 13 million, and Florida trounces one-day case record set by California last week
- The number of confirmed cases of the coronavirus illness COVID-19 worldwide edged closer to 13 million on Monday, a day after the World Health Organization...
- 07/13/2020
|
Strong demand for virus testing services; snacking surges
- Quest Diagnostics is seeing growing demand for its COVID-19 testing services
- 07/13/2020
|
Quest Diagnostics revenue tops expectations on demand for coronavirus testing services
- Quest Diagnostics reported preliminary second-quarter revenue above analysts' estimates on Monday, largely on growing demand for its Covid-19 testing services, sending its shares up 2.7% before the bell.
- 07/13/2020
|
Quest sees Q2 revenue above estimates on demand for COVID-19 testing services
|
Quest Diagnostics shares rise premarket after guidance that blows past estimates
- Quest Diagnostics Inc. said Monday it expects second-quarter revenue of about $1.83 billion, a decline of about 6% from the year-earlier period but well ahead of the $1.53 billion FactSet consensus. Testing volumes in the company's base business, which excludes COVID-19 molecular and antibody testing, fell about 18%, the company said. It now expects per-share earnings of $1.33 to $1.36, compared with $1.51 a year ago. Adjusted EPS is expected to range from $1.39 to $1.42, compared with $1.73 in 2019 and a the FactSet consensus of 16 cents. The company will report second-quarter earnings on July 23. "The company continues to believe that the pandemic's impact on its future operating results, cash flows and/or financial condition will be primarily driven by: the pandemic's severity and duration; the pandemic's impact on the U.S. healthcare system and the U.S. economy; and the timing, scope and effectiveness of federal, state and local governmental responses to the pandemic which are drivers beyond the company's knowledge and control," Quest said in a statement. Shares rose 2.4% premarket, and have gained 9.4% in the year to date, while the S&P; 500 has fallen 1.4%.
- 07/13/2020
|
Quest Diagnostics Announces Preliminary Second Quarter 2020 Financial Results
- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today preliminary financial results for the second quarter ended June 30, 2020. The results reflect stronger than forecasted recovery in base testing volumes (excluding COVID-19 molecular and antibody testing) as well as growing demand for COVID-19 testing services.
- 07/13/2020
|
Quest Diagnostics (NYSE:DGX) Issues Q2 2020
Pre-Market Earnings Guidance
- Quest Diagnostics (NYSE:DGX) issued an update on its second quarter 2020 Pre-Market earnings guidance on Monday morning. The company provided earnings per share guidance of 1.39-1.42 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.12. The company issued revenue guidance of $1.83-1.83 billion, compared to the consensus revenue estimate […]
- 07/13/2020
|
Wedge Capital Management L L P NC Has $771,000 Stake in Quest Diagnostics Inc (NYSE:DGX)
- Wedge Capital Management L L P NC decreased its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 22.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,769 shares of the medical research company’s stock after selling 2,011 shares […]
- 07/13/2020
|
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
- Stocks Analysis by Zacks Investment Research covering: Baxter International Inc, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, West Pharmaceutical Services Inc. Read Zacks Investment Research's latest article on Investing.com
- 07/10/2020
|
LabCorp Launches At-Home Coronavirus Test Collection Kit
- LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
- 07/08/2020
|
BD Receives EUA for New Antigen Test to Combat COVID-19
- Becton, Dickinson (BDX) receives EUA from the FDA for a rapid, point-of-care, antigen test to detect SARS-CoV-2 in 15 minutes.
- 07/08/2020
|
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
- By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
- 07/08/2020
|
5 Stocks With Relative Price Strength to Enhance Your Returns
- Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
- 07/08/2020
|
HPV Test Misses Twice as Many Women Who Develop Cervical Cancer as Cotesting, Quest Diagnostics Health Trends™ Study Finds
- A Health Trends™ study from researchers at Quest Diagnostics (NYSE: DGX) and the University of Pittsburgh Medical Center (UPMC) provides new evidence that the HPV screening test is significantly less likely to detect cervical cancer and precancer than cotesting, a method which combines HPV and Pap (Papanicolaou test by liquid based cytology) testing using the same specimen.
- 07/08/2020
|
Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge
- Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.
- 07/07/2020
|
Outlook for Diagnostics Sector Tests Positive
- The Covid-19 crisis has been very good to companies making tests and that isn’t likely to disappear once the current wave of infections does.
- 07/07/2020
|
Align Technology's Rollouts Aid Amid Procedural Deferrals
- Align Technology's (ALGN) new virtual solutions ensure continuity of care amid pandemic.
- 07/07/2020
|
Thermo Fisher Stock Rises on Solid Q2 Growth Expectation
- Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.
- 07/07/2020
|
Dividend Changes: June 27-July 3, 2020
- This article series provides a weekly summary of dividend changes, including dividend increases and dividend cuts or suspensions.
- 07/07/2020
|
QUEST DIAGNOSTICS : Ex-dividend day for | MarketScreener
|
Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge
- Stocks Analysis by Zacks Investment Research covering: Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Myriad Genetics Inc. Read Zacks Investment Research's latest article on Investing.com
- 07/07/2020
|
Quest Diagnostics : Media Statement about COVID-19 Testing | MarketScreener
|
Here's Why You Should Invest in OPKO Health (OPK) Stock Now
- OPKO Health (OPK) continues to benefit from lucrative prospects in RAYALDEE and BioReference platforms.
- 07/06/2020
|
Luminex Boosts Product Portfolio With New xMAP Technology
- Luminex (LMNX) commences rollout of new xMAP INTELLIFLEX Systems, which will expand its xMAP Technology.
- 07/06/2020
|
Dividend Challenger Highlights: Week Of July 5
- A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies wi
- 07/05/2020
|
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
- Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/03/2020
|
Is Quest Diagnostics (DGX) Outperforming Other Medical Stocks This Year?
- Is (DGX) Outperforming Other Medical Stocks This Year?
- 07/03/2020
|
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
- IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.
- 07/03/2020
|
Boston Scientific's (BSX) ICM System Receives FDA Approval
- Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
- 07/03/2020
|
Buy Opko Stock For Two Ways to Play the Ongoing Pandemic
- Like the rest of us, Wall Street is obsessed with the novel coronavirus. Seemingly every company has some sort of Covid-19 angle, from creating personal protective gear, manufacturing medical equipment, creating or running tests and working on a vaccine. Those that have a successful angle are richly rewarded. That's where we are lately with Opko Health (NASDAQ:OPK) stock.Source: Shutterstock.com Opko, a midsize Miami-based company with a market cap of just over $2 billion, is up more than 130% so far this year. And while shares are still less than $4, the company is now trading at levels unseen since January 2019.What's driving OPK stock higher? It's Covid-19, of course? This company has two ways to play the pandemic.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Opko's Coronavirus TreatmentOpko is putting its hopes on Rayaldee, which goes by the generic name of calcifediol. Rayaldee capsules are used to treat patients with hyperparathyriodism, stage 3 or stage 4 chronic kidney disease or low vitamin D levels. * 7 Utilities Stocks to Buy With Reassuring Dividends In June, the Food and Drug Administration approved Opko's request for a Phase 2 trial of 166 patients with mild to moderate cases of Covid-19. The patients are taking Rayaldee for four weeks in a randomized double-blind placebo-controlled study to see if it can successfully raise levels of serum total-25 hydroxyvitamin D (25D) levels to reduce the effects of the coronavirus symptoms.Opko says many of the subjects of the study have advanced-stage kidney disease.Dr. Charles Bishop, CEO of Opko's renal division, explained the test:"Raising serum 25D enables macrophages, a type of white blood cell of the immune system, to secrete potent antiviral proteins that can destroy SARS-CoV-2, the virus that causes COVID-19. It also can suppress the cytokine storm triggered by viral infection."Sure, there are a lot of coronavirus trials and potential vaccines out there, including efforts by Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). So, there's no guarantees that OPK stock will benefit from its Phase 2 trial.The market sentiment in certainly strong, however. Since the June 1 announcement, Opko stock is up 50%. Opko's Coronavirus TestA sure-fire revenue stream for Opko, however, is testing for the coronavirus. Currently the U.S. is conducting 500,000 tests per day and so far has issued more than 32 million tests.We have a long way to go before this pandemic is over. Experts say the U.S. should be doing 1 million or more tests per day, and that the need for tests will last long after a vaccine is created and mass-produced.Opko subsidiary BioReference Laboratories is among those performing coronavirus tests. BioReference is the contracted lab in New York City, which was the epicenter of the Covid-19 pandemic for several months, and the city is still offering free testing performed by BioReference at 16 locations.BioReference also has a contract with New York state, which has been aggressive in testing to flatten the curve of new cases. It recently published a study of testing at New York nursing home and adult care facilities. The testing included more than 350 facilities and included 222,000 Covid-19 tests and 3,500 antibody tests.Jon Cohen, executive chairman of BioReference, told Politico that the company is also conducting tests in New Jersey and Florida -- the latter which is currently seeing its own spike in new cases. He said BioReference and other testers are straining to keep up with the demand for testing."We not only hit capacity, but any ability to increase our capacity became limited by the supply side," he said. "The vendors, the suppliers can't keep up."That doesn't sound like demand that's going to go away any time soon. Vendors and suppliers will adapt to the increased need, much as they did for toilet paper and hand sanitizer back in March. You can expect revenues to continue to flow into Opko's coffers. OPK Stock at a GlanceOpko reported first-quarter earnings in early May, posting revenue of $211.5 million versus analysts' expectations of $215.9 million. Earnings came in at an adjusted loss of $0.09 per share, which matched expectations.I'm expecting better numbers for the second quarter when Opko reports in early August, considering the number of coronavirus tests it has performed and its Phase 2 testing with Rayaldee.And I'm not the only one. Piper Sandler analyst Edward Tentoff raised his price target on OPK stock from $3 to $4, saying BioReference's testing should give Opko's Services division nearly $900 million in revenue this year. The Bottom Line on OPK StockOpko isn't the biggest biotech name on the market. And it's not as big as testing competitors Quest Diagnostics (NYSE:DGX) or LabCorp parent Laboratory Corporation of America (NYSE:LH).But as a growth stock with potential to provide oversized returns, I like Opko for giving investors two paths to profit from coronavirus research and testing.OPK stock has a "B" grade in my Portfolio Grader right now, where it carries a buy recommendation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Buy Opko Stock For Two Ways to Play the Ongoing Pandemic appeared first on InvestorPlace.
- 07/02/2020
|
Long lines as Alabama cities see new demand for coronavirus testing
- As demand increases, the ease of getting a COVID-19 test varies, according to AL.com readers.
- 07/02/2020
|
Myriad Genetics Unveils New Home DNA Sample Collection Kit
- Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.
- 07/02/2020
|
Should You Be Adding Quest Diagnostics (NYSE:DGX) To Your Watchlist Today?
- For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- 07/02/2020
|
Quest Diagnostics Inc (NYSE:DGX) Expected to Announce Quarterly Sales of $1.54 Billion
- Brokerages expect that Quest Diagnostics Inc (NYSE:DGX) will report $1.54 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Quest Diagnostics’ earnings, with the highest sales estimate coming in at $1.82 billion and the lowest estimate coming in at $1.37 billion. Quest Diagnostics posted sales of $1.95 […]
- 07/02/2020
|
As demand for COVID-19 testing surges, results lag in labs
- As more people seek testing, commercial laboratories doing the bulk of Houston’s molecular diagnostic tests for the novel coronavirus are becoming more overwhelmed by requests for processing.
- 07/01/2020
|
New Tool Will Help Insurers, State Officials Predict Health Costs From Pandemic
- The publicly available tool, funded by a Robert Wood Johnson Foundation grant, may help companies trying to set their premiums for 2021. In other news, insurers offer new options for COVID-19 testi…
- 07/01/2020
|
Masimo's New Solution to Reduce Opioid Withdrawal Symptoms
- Masimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment.
- 07/01/2020
|
Change your RealAge to help overcome the isolation blues
- Q: I’m lonely and blue after three months of isolation. What can I do to regain a more connected feeling? I’m 68, I live by myself and am not working. Karen G., New York City A: You’re not alone in feeling depressed and lonely. Around 35.7 million Americans live by themselves, and since the start of the pandemic, many have had no real social contact. Older folks may be most affected by isolation — depending on their perceived RealAge! A new study of folks age 58-72 found that COVID-related loneliness can trigger depression, anxiety and trauma symptoms, but only among those seniors who felt they were older than their chronological age. Folks who felt their RealAge was younger than their years had no psychiatric symptoms related to loneliness. So, it makes sense to take a look at how you might achieve a younger RealAge and tamp down feelings of depression and loneliness. Volunteer — virtually, if necessary. Research published in the American Journal of Preventive Medicine found that over the four years of the study, those who volunteered for at least two hours per week had a substantially reduced risk of developing physical limitations or dying. Volunteers also were more physically active and had an improved sense of well-being. So, contact local charities and community groups to see what you can do for them, then go to aarp.com and search for “volunteer online.” Stress reduction techniques can help overcome the emotional impact of loneliness and create a younger RealAge. Try yoga, tai chi, mindful meditation and massage therapy. Go to sharecare.com for articles, instructions and videos. Physical activity promotes a younger RealAge and improves...
- 07/01/2020
|
Cognitive Assessment and Training Market 2020-2024 | Cost-Effective Online Cognitive Assessments to Boost Growth | Technavio
- The Global Cognitive Assessment and Training Market will grow by $ 13.56 bn during 2020-2024
- 07/01/2020
|
Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe
- The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.
- 06/30/2020
|
Insurer Humana teams up with Walmart, Quest, LabCorp for COVID-19 testing
- U.S. health insurer Humana Inc will offer its members at-home COVID-19 test collection kits, as well as provide access to drive-through testings at the hundreds of neighborhood markets of Walmart Inc, it said on Tuesday. For drive-through testing, the insurer said it has tied up with the retail chain and Quest Diagnostics. Humana said new testing sites at Walmart pharmacies will be added between now and August for pharmacist-observed testing.
- 06/30/2020
|
Luminex Expands COVID-19 Testing With New Antibody Test
- Luminex (LMNX) submits an EUA request to the FDA for its first multi-antigen IgG assay.
- 06/30/2020
|
Quest Diagnostics Marks 10 Years of Commitment to Reducing Employee Cancer Risk as CEO Cancer Gold Standard™ Employer
- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, marks its 10-year anniversary as a CEO Cancer Gold Standard™ employer this year, signifying its commitment to implementing employee health strategies that will reduce cancer risk among its workforce.
- 06/30/2020
|
Humana to Offer LabCorp At-Home COVID-19 Test Collection and Collaborate with Walmart and Quest Diagnostics to Offer Drive-Thru Testing for Humana Members
- Leading health and well-being company Humana Inc. (NYSE: HUM) announced a pilot home-testing program today that will enable at-home COVID-19 test coll
- 06/30/2020
|
Quest Diagnostics : Media Statement about COVID-19 Testing | MarketScreener
|
Renalytix AI Looks For U.S. Public Capital In IPO Filing
- Renalytix AI has filed to raise $86 million in a U.S. IPO. The firm is developing a chronic kidney disease diagnostic system. RNLX is still in development stage
- 06/29/2020
|
Myriad Genetics' myPath Melanoma Proved Superior Per New Study
- Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.
- 06/29/2020
|
Here's Why You Should Hold on to Illumina Stock for Now
- Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.
- 06/29/2020
|
CEO Roundtable on Cancer : Celebrates Employers marking Ten-Year CEO Cancer Gold Standard™ Anniversary | MarketScreener
|
CEO Roundtable on Cancer Celebrates Employers marking Ten-Year CEO Cancer Gold Standard™ Anniversary
- The CEO Cancer Gold Standard™, the employer-led health and wellness accreditation program of the CEO Roundtable on Cancer, is now helping more than seven million employees and their family members prevent and address cancer through workplace-based programming. This year, 18 Gold Standard employers mark their ten-year anniversary as Gold Standard employers, having maintained a strong commitment to the health of their employees and satisfying the latest, comprehensive requirements of the Gold Standard.
- 06/29/2020
|
Guggenheim Capital LLC Sells 19,074 Shares of Quest Diagnostics Inc (NYSE:DGX)
- Guggenheim Capital LLC cut its position in Quest Diagnostics Inc (NYSE:DGX) by 16.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,624 shares of the medical research company’s stock after selling 19,074 shares during the quarter. Guggenheim Capital LLC owned about 0.07% of […]
- 06/28/2020
|
500 Delta Airline staff test positive for COVID-19, records 10 deaths - Businessday NG
- Delta Air Lines says an estimated 500 employees have contracted coronavirus during the pandemic — and the virus has killed at least 10, according...
- 06/25/2020
|
Virus testing, tracking still plagued by reporting delays
- ATLANTA (AP) - As part of the plan to restart its season next month, the NBA is preparing to test hundreds of players, coaches and others for the coronavirus each night inside a "basketball bubble" - a space at the Disney complex near Orlando, Florida, with extra protection against the disease.
Test results will be expected back the next morning, before the day's practices and games begin. That sort of rapid turnaround is the gold standard for tracking a highly contagious disease that is on the rise again in parts of the country. Yet an Associated Press survey of selected U.S. states shows the benchmark is rarely met for the general public.
Having access to quick test results will play an important role in resuming sporting events, keeping businesses and factories open, and returning to school in the fall. But the AP survey found it sometimes still takes days for results to be returned, despite an increase in the availability of testing across the country.
The situation is even worse in many hot spots around the world, including South Africa, where results have sometimes taken up to 12 days.
Judy Clinco, owner of Catalina In-Home Services in Tucson, Arizona, has had to test about 30 of her 110 staffers, who provide care and assistance to seniors in their homes. They are not able to visit clients until the results are back, which typically takes a week to 10 days.
As many as seven employees have been sidelined at once, Clinco said.
"During that time, the caregiver is not working. We are subsidizing their wages, and it's a financial burden to the company," she said. "It leaves us with one less caregiver to be on assignment, and that leaves us short-staffed."
Public health experts say testing delays present a major hurdle to reducing infections and...
- 06/25/2020
|
Virus testing, tracking still plagued by reporting delays
- Having access to quick coronavirus test results will play an important role in resuming sporting events, keeping factories and businesses open, and returning to school in the fall
- 06/25/2020
|
Coronavirus tests could still take up to 10 DAYS in some states
- CDC guidelines say that reopening states should return coronavirus test results within 48 hours, but an AP survey suggests wait times may be longer in states like Arizona, New York and Georgia.
- 06/25/2020
|
Virus testing, tracking still plagued by reporting delays
- ATLANTA (AP) - As part of the plan to restart its season next month, the NBA is preparing to test hundreds of players, coaches and others for the coronavirus each night inside a "basketball bubble" - a space at the Disney complex near Orlando, Florida, with extra protection against the disease.
Test results will be expected back the next morning, before the day's practices and games begin. That sort of rapid turnaround is the gold standard for tracking a highly contagious disease that is on the rise again in parts of the country. Yet an Associated Press survey of selected U.S. states shows the benchmark is rarely met.
Having access to quick test results will play an important role in resuming sporting events, keeping businesses and factories open, and sending students back to school in the fall. But the AP survey found it sometimes still takes days for results to be returned, despite an increase in the availability of testing across the country.
Judy Clinco, owner of Catalina In-Home Services in Tucson, Arizona, has had to test about 30 of her 110 staffers, who provide care and assistance to seniors in their homes. They are not able to visit clients until the results are back, which typically takes a week to 10 days.
As many as seven employees have been sidelined at once, Clinco said.
"During that time, the caregiver is not working. We are subsidizing their wages, and it's a financial burden to the company," she said. "It leaves us with one less caregiver to be on assignment, and that leaves us short-staffed."
Public health experts say testing delays present a major hurdle to reducing infections and tracking those who have been in close contact with a person who is positive for the virus.
That's why researchers are working to develop rapid tests...
- 06/25/2020
|
Virus testing, tracking still plagued by reporting delays
- ATLANTA (AP) — As part of the plan to restart its season next month, the NBA is preparing to test hundreds of players, coaches and others for the coronavirus each night inside a “basketball...
- 06/25/2020
|
Ooma, Chico's, Ericsson, Quest and Kroger as Zacks Bull and Bear of the Day
- Ooma, Chico???s, Ericsson, Quest and Kroger as Zacks Bull and Bear of the Day
- 06/25/2020
|
Ecolab's New Pest Elimination Service to Ensure Food Safety
- Ecolab's (ECL) introduces Rodent Ceiling Service, which can help reduce the risk to food safety and public health.
- 06/25/2020
|
Coronavirus live updates: Germany pledges support to WHO; LabCorp launches new antibody test
- The coronavirus has infected more than 9.44 million people around the world as of Thursday, killing at least 482,923 people.
- 06/25/2020
|
Virus testing, tracking still plagued by reporting delays
- ATLANTA - As part of the plan to restart its season next month, the NBA is preparing to test hundreds of players, coaches and others for the coronavir...
- 06/25/2020
|
Delta says 10 employees dead from coronavirus, 500 infected
- Delta Air Lines says an estimated 500 employees have contracted coronavirus during the pandemic — and the virus has killed at least 10, according to a report. CEO Ed Bastian said at a sharehl…
- 06/24/2020
|
CVS to offer companies COVID-19 testing program as U.S. cases rise
- As U.S. employers grapple with trying to keep workers healthy and on the job amid fresh spikes in COVID-19 cases, CVS Health Corp has begun selling companies a diagnostic testing program.
- 06/24/2020
|
Conformis Next-Generation Identity PS Knee System Gets FDA Nod
- Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.
- 06/24/2020
|
3 Best GARP Stocks to Beat Pandemic-Led Market Inefficiency
- The unprecedented global health crisis is providing a psychological shock to the investment world.
- 06/24/2020
|
Patterson Companies (PDCO) Q4 Earnings Top Estimates, Up Y/Y
- Patterson Companies' (PDCO) fiscal fourth-quarter results reflect dismal performance by Dental and Animal Health segments.
- 06/24/2020
|
Masimo (MASI) Boosts Product Portfolio with New Solution
- Masimo (MASI) unveils Masimo Sleep to help consumers better understand their quality of sleep.
- 06/24/2020
|
CVS to offer employers COVID-19 testing program as U.S. cases rise
- As U.S. employers grapple with trying to keep workers healthy and on the job amid fresh spikes in COVID-19 cases, CVS Health Corp has begun selling companies a diagnostic testing program.
- 06/24/2020
|
CVS to offer employers COVID-19 testing program as U.S. cases rise
- As U.S. employers grapple with trying to keep workers healthy and on the job amid fresh spikes in COVID-19 cases, CVS Health Corp has begun selling companies a diagnostic testing program. The unexpected surge in COVID-19 cases in states in the South and West has increased demand in recent weeks for testing workers on a regular basis, such as every two weeks or every month, said Troy Brennan, chief medical officer of the company, which operates pharmacies, a pharmacy benefit management (PBM) service and the Aetna insurance plan. States including Florida, Arizona, and Texas, as well as Georgia, Oklahoma, South Carolina and Utah have all reported an increase in COVID-19 cases and hospitalizations in recent weeks.
- 06/24/2020
|
Global Prenatal Diagnostics Industry to 2027 - Market Trajectory & Analytics - ResearchAndMarkets.com
|
Arizona's main COVID lab running behind as demand for tests soars to twice capacity
- A spike in coronavirus infections in Arizona pushed demand for tests to twice the capacity of the state's main COVID lab last week, a senior laboratory executive said, adding that new testing equipment had been delayed two months. The Arizona delays - in testing and results reporting - are similar to problems seen earlier in the epidemic, and some labs across the country are facing shortages of supplies, an industry group said. In Arizona, Roche Holding recently told Sonora Quest lab, a joint venture between Phoenix-based Banner Health and Quest Diagnostics, that a new instrument it had hoped to get in June would not be delivered until August, said Sonora Chief Operating Officer Sonya Engle.
- 06/23/2020
|
Quest Diagnostics : to Expand in Indiana with Acquisition of Outreach Lab Businesses of Community Health Network and Ascension St. Vincent Now Serviced Through Mid America Clinical Laboratories | MarketScreener
|
Quest Diagnostics to Expand in Indiana with Acquisition of Outreach Lab Businesses of Community Health Network and Ascension St. Vincent Now Serviced Through Mid America Clinical Laboratories
- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the formation of a definitive multi-pronged agreement designed to optimize the delivery of high quality, innovative diagnostic laboratory services in Indiana.
- 06/23/2020
|
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
- Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.
- 06/23/2020
|
Medtronic's Evolut TAVI Gets CE Mark for Low-Risk Patients
- Medtronic's (MDT) Evolut system shows a lower rate of the composite of all-cause death or disabling stroke with TAVI at 30 days.
- 06/23/2020
|
